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Abstract
Aortic stenosis due to degenerative calcific aortic valvular disease is the most reason for
aortic valve replacement in developed countries. Aortic stenosis affects up to 7% of the world
population, and current clinical data indicate that the number of the affected people could be
triple by 2050, due to population ageing and health lifestyle. Transcatheter aortic valve
replacement (TAVR) was introduced as a minimal invasive treatment of severe aortic stenosis.
Even though surgical aortic valve replacement (SAVR) is considered the golden standard
treatment for severe aortic stenosis patients, TAVR showed equivalent or even superior outcome
compare to SAVR. Currently, transcatheter aortic valves (TAVs) have limited clinical data in
term of fluid dynamics performance of TAVs, in contrast to surgical aortic valves (SAVs). Due
to limitations associated with devices that are used to evaluate the performance of TAVs in
patients such as echocardiography, magnetic response imaging (MRI) and an accurate method to
detect and evaluate any leakage. Thus, an experimental testing and computational modeling were
performed to compare the performance of TAVs to SAVs in term of hemodynamic performance
and addressing some clinical complications that are associated with TAV devices. Therefore, the
objectives of this dissertation were to used particle image velocimetry (PIV) to obtain velocity
and shear stress contours to indicate any damage to blood elements that could lead to stroke.
Additionally, investigate the cause of reduced TAV leaflets motion post-TAVR procedure using
blood residence time (BRT) approach. Furthermore, validating the current guideline uses to
evaluate paravalvular leakage (PVL) severity and develop a new methodology to assess and
evaluate the severity of PVL post-TAVR based on fluid dynamics. Moreover, developing and
validating non-invasive procedure to estimate energy loss post-TAVR during the cardiac cycle
ii

and determine the workload imposes on the left ventricular. Thus, the main goal of this
dissertation was to develop experimental testing to measure hemodynamics performance of TAVs
and validating computational modeling output in term of flow field.
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Chapter 1: Introduction
1.1 Anatomy and Structure of the Heart
The human heart function is to pump oxygenated blood from the heart into the rest of the
body. The heart is located between the two lungs in the middle of the chest. The heart has two
sides, each side divided into two chambers which are separated by valves as shown in Fig. 1.1.
The upper chamber is known as the atrium, while lower is known as ventricle. In this dissertation,
I focused on the left side of the heart which consist of the left atrium and ventricular. The left
atrium and ventricle are separated by mitral valve, while the left ventricle and aorta are separated
by aortic valve. The main function of the aortic valve is to prevent backward flow of blood, and
to ensure one directional blood flow.
On the other hand, the cardiac cycle is divided into two phases: diastole and systole.
When the left ventricle contracts, blood pumps out (forward flow) through the aortic valves into
the aortic ascending then into the rest of the body. The aortic valve has three flaps called leaflets,
they open and close during systole and diastole, respectively. During the diastole phase, the mitral
valve opens to allow blood flow from left atrium into the left ventricle. While in systole phase,
the left ventricle contracts opening the aortic valve allows blood flow out of the heart into the
body. Wiggers diagram is shown in Fig. 1.2, which illustrate the motion of blood with respect to
volume, pressure and valves movement during the cardiac cycle. The Pressure in left ventricular
must exceed the pressure in the aorta among normal patients during systole. In addition, pressure
of the left atrium is usually between 2 to 8 mmHg and pressure of left ventricle is between 2 to
120 mmHg. On the other hand, aortic pressure is usually from 80 to 120 mmHg.
1

Figure 1.1: Anatomy structure of the human heart. Red arrow shows blood flow direction in left
ventricle. Blue arrow shows blood flow direction in the right ventricle. Adopted from (Regina
Bailey 2019)

Figure 1.2: Illustrate pressure waveform diagram during the cardiac cycle. Adopted from (Robert
Carroll 2007).
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1.2 Valvular Disease
The main function of the heart valves is to arrange the motion of the blood and prevent
blood moving backward. Valvular disease is one of the major causes of death in developed
countries (Iung et al., 2003). There are several causes of valvular disease such as: age, infection,
lifestyle, rheumatic fever and valve calcification. Stenosis and regurgitation are the most common
valvular disease in the world. Valve stenosis occurs when the valve leaflets narrow where the
valve does not open fully due to calcification, which results in reduce blood flow through the
valve. On the other hand, valve regurgitation occurs when the valve leaflets don’t close properly,
leading to backward blood flow. In 2015, the total number of living people with valvular disease
was 33.4 million (Association, 2017; Benjamin, Muntner, & Bittencourt, 2019). In the United
States, the total of death due to valvular disease is 139,229 (Bevan, Zidar, Josephson, & AlKindi, 2019).
1.3 Aortic Stenosis
Each year approximately 300,000 people in the United States are diagnosed with sever
aortic stenosis. Systemic severe aortic stenosis is linked to high mortality rates, up to 50% per
year (Bevan et al., 2019; Nkomo et al., 2006). The prevalence of aortic stenosis is more likely to
increase as population ages (Coffey et al., 2014). Aortic stenosis could be a result of degenerate
calcified trileaflet aortic valve or a congenital heart defect bicuspid aortic valve. Generally, aortic
stenosis prevents the aortic valve from opening fully, resulting in reducing oxygenated blood flow
forward through the valve due to the present of the calcified or defected valve. In this case, the
heart must work harder to compensate the body with the needed oxygenated blood.
The severity of aortic stenosis is classified as mild, moderate and severe based on
measuring the opening area of aortic valve using echocardiography (Vahanian & Otto, 2010).
Symptoms of aortic stenosis can be different or may not be present in most patients, especially
3

among mild and moderate patients. However, patients with severe aortic stenosis usually have the
following symptoms: angina, syncope and or dyspnea (Vahanian & Otto, 2010). After classifying
the severity of aortic stenosis, a special team of cardiologists will determine the best treatment
option for the patient.
The classical treatment for aortic stenosis is surgical aortic valve replacement (SAVR),
where the damaged valve repaired and is replaced it with a new valve. However, TAVR is
considered an effective treatment with less mortality rate and fast recovery time compared to
SAVR (Aranki et al., 1993). However, SAVR is an invasive procedure which requires an open
heart surgery, either with a mechanical or bioprosthetic heart valve, is a gold standard treatment
for patient with severe aortic stenosis (Walther, Blumenstein, van Linden, & Kempfert, 2012). On
the other hand, SAVR may not be an effective treatment for old patients, especially patients
whom are at high risk of open-heart surgery. Therefore, transcatheter aortic valve replacement
(TAVR) has emerged as a safe alternative treatment to SAVR.
1.4 Surgical Aortic Valve Replacement
SAVR is the treatment of choice for patients with severe aortic stenosis. In this
procedure, an incision is made in the chest to access the aortic valve location. The calcified, or
defected, aortic valve is removed and replaced with either a mechanical valve or a bioprosthetic
valve as shown in Fig. 1.3. The mechanical heart valve is more durable and reliable; however,
patients with mechanical heart valve must receive anticoagulant for the rest of their life, due to
the thrombogenicity of the mechanical valves material. On the other hand, bioprosthetic aortic
valves (BAVs) were introduced for patient who cannot take anticoagulant.
Generally, BAVs are made of bovine pericardium or porcine aortic valves, also it can
be made from equine pericardium. The best advantage of BAVs is that patients are not required to
receive anticoagulant. Additionally, BAVs material has shown long term durability in term of
4

stress distribution on the leaflets. BAVs perform to imitate the one-way blood flow as the normal
valve, by sealing valve leaflet against each other, or it can be stented or stentless as shown in
Fig.1.4. Surgical aortic valves (SAVs) have shown good outstanding in term of their
biocompatibility and hemodynamic performance; however, SAVs are less durable than
mechanical valve . The Capentier-Edwards (CE) PERIMOUNT pericardial bioprosthesis
(Edwards Lifesciences, Irvine, CA) as shown in Fig. 1.4 has an excellent freedom from structural
valve deterioration and satisfaction in term of hemodynamic performance up to 18 years of
operation. However, SAVs may not be a recommended treatment option, especially for patient at
high-risk of open-heart surgery.

Figure 1.3: (A) Mechanical heart valve (courtesy of www.heart-valve-surgery.com). (B)
Bioprosthetic heart valve (courtesy of www.edwards.com).

5

Figure 1.4: (A) Stented pericardial bovine bioprosthetic valves. (B) Stented porcine aortic valve
bioprostheses. (C) Stentless bioprosthetic valves. CE = Carpentier-Edwards; SPV = stentless
porcine valve, permission from (Piazza et al. 2011).

1.5 Transcatheter Aortic Valve Replacement
Current clinical trials are investigating outcomes of transcatheter aortic valve replacement
(TAVR) among patient at intermediate-risk and low-risk of an open surgery (Carabello, 2011;
Chakos et al., 2017; Coylewright, Forrest, McCabe, & Nazif, 2020; Daubert et al., 2017;
Kheradvar et al., 2015; M. Leon et al., 2010; M. B. Leon et al., 2016; Linden, Leon, Smith, Mack,
& Investigators, 2011). TAVR procedure is performed using one of the four different approach to
access the aortic valve location: transfemoral, transapical, transaortic and transcarotid (Barbanti,
Webb, Gilard, Capodanno, & Tamburino, 2017). A team of cardiologists will determine which
6

appropriate way to deliver the TAV into the calcified native aortic valve, however, the
transfemoral approach is the most common way to deliver TAV. During the transfemoral
approach, a small incision is made in the leg, and a catheter is inserted and traveled into the artery
while the heart is beating. The team will guide the catheter and place it within the damaged valve.
TAV can be delivered via chest for patients whom have vascular anatomy issues, transcarotid
arterial access may be an alternative solution. Despite TAV industries use similar material leaflets
as SAV, and therefore, TAV is expected to degenerate via similar mechanisms. However, TAVs
design and implant configuration are totally different from SAVs (Thourani et al., 2015).
One of the most advantages of TAVR procedure is short recovery time (3-5 days)
compare to SAVR which its recovery time about three months (Rodés-Cabau, 2012). Since
TAVR was established, there has been more than 350,000 patient underwent TAVR procedure in
70 different countries (Webb et al., 2007). Currently, there are several designs of TAV that are
commercially available as shown in Fig. 1.5. Even though, TAVR is less invasive procedure for
patient with high risk of an open heart surgery with short recovery time, SAVR is still quite the
golden standard for treating patient with aortic stenosis (Barbanti et al., 2017). TAVR is currently
being investigated in a clinical trial among low risk patients of open heart surgery (Coylewright et
al., 2020; Kodali et al., 2012; Sondergaard, 2016). Nevertheless, TAVs lack to more data in term
of hemodynamic performance and its impact on the cardiac cycle, in contrary to SAVs.

7

Figure 1.5: Different design configuration of TAVs devices that are currently available.
permission from (Sondergaard, 2016).
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1.6 Clinical issues associated with TAVR
1.6.1 Cerebral Embolisms
In the last decade TAVR has been introduced as a treatment option for patients with
severe aortic stenosis. However, cerebral embolism complication was seen early as a potential
clinical issue (Kheradvar et al., 2015). A published clinical data shows that there is no increase of
stroke among patients who underwent TAVR vs surgical replacement (Adams et al., 2014;
Makkar et al., 2012). Several magnetic respond imaging (MRI) studies (Arnold et al., 2010;
Astarci et al., 2011; Ghanem et al., 2010; Hamm et al., 2013; Kahlert et al., 2009) have shown
that cerebral embolism was observed in the majority of TAVR patients with a few days after the
procedure. The issue of cerebral embolism could be originated from several places such as the
native calcified valve or the aortic. Even with the use of a device to protect embolism from
traveling to the brain, the majority of TAVR still show evidence of cerebral embolism (Lansky et
al., 2015). To expand the use of TAVR to low-risk patient of aortic stenosis, the sources of
cerebral emboli must be understood to prevent such an issue from occurring.

Figure 1.6: MRI results of 4 patients showing location of cerebral embolism without clinical
stroke or TIA event. (A) single right embolus. (B) Multiple embolism in left and right of the
brain. Permission from (Van Belle et al., 2016).
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1.6.2 Reduced motion of TAV Leaflet
Another major clinical complication post-TAVR is that reduce leaflet motion has been
reported in several clinical studies (De Marchena et al., 2015; Egbe et al., 2015; Leetmaa et al.,
2015; Makkar et al., 2015; Van Belle et al., 2016). Reduced leaflet motion was detected among
multiple bioprosthesis valves, including TAVs and SAVs. Additionally, valvular thrombosis was
observed in patients following TAVR even days post the procedure (Akhras et al., 2016; De
Marchena et al., 2015; Latib et al., 2015; Martí et al., 2015). A clinical study using 4-D volume
computed tomography (CT) reported that valvular thrombosis has been found to be on the aortic
surface of the valve leaflets and to the lesser extent of the ventricular surface (Del Trigo et al.,
2016; Makkar et al., 2015). However, reduced leaflet motion is less among patients with surgical
bioprosthesis (De Marchena et al., 2015; Egbe et al., 2015; Grunkemeier & Rahimtoola, 1990).

Figure 1.7: TAV device implanted over the native aortic valve. (A) TAV stent is surrounded
around the native calcified aortic valve. Permission from (Brown, Park, Sundt, & Schaff, 2012). (
B) The presence of thrombosis on the aortic surface of a SAPIEN valve following TAVR.
Permission from (Krishnaswamy, Kapadia, & Tuzcu, 2012).
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1.6.3 Paravalvular Leakage post-TAVR
Unlike surgical valve where a surgeon removed the calcified native or degenerated
bioprosthetic valve, and replace it with a surgical valve, TAVR is implanted using a catheter to
expand the TAV device over the calcified native valve or a degenerated bioprosthetic valve.
Therefore, incomplete expansion of TAV, might lead to paravalvular leakage (PVL). The severity
of PVL graded as mild, moderate and severe depending on the total volume of the leakage during
TAV closure. Despite the possibility of measuring the volume of PVL, estimating the severity of
PVL remains challenging. A clinical study has reported a mild PVL in 38% and moderate/severe
in 9.1% of patients post-TAVR (De Marchena et al., 2015; Vahl, Kodali, & Leon, 2016). The rate
of morbidity and mortality has been dramatically increased among TAVR patients due to PVL,
even in mild PVL cases (Dencker et al., 2016; Rodés-Cabau, 2012). Clinically, it has been reported
that moderate and severe PVL severity was seen more in self-expanded valve than balloonexpanded valve following TAVR (Gotzmann et al., 2012).

Figure 1.8: Echocardiography short axis view of SAPIEN 3 after one day of implementation.
Permission from (Athappan et al., 2013)
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1.7 Objectives
Fluid dynamics has been known to play a critical role in thrombotic and hemolytic
complications associated with bioprosthetic aortic valves. Therefore, the first objective of this
study was to characterize and measure hemodynamic performance of transcatheter aortic valves
under physiological conditions. Previously, its well know that both high shear stress magnitude
and exposure time is associated with blood elements damage and platelet activation. In the
presence of high shear stress magnitude, the likelihood of blood clot and thrombosis formation
increase leading to serious clinical complications. Additionally, computer simulations have been
leading approach in the design and verification of bioprosthetic aortic valves, therefore the
particle image velocimetry (PIV) images obtained from the experimental result will provide
validation of computational fluid dynamic (CFD) results.
Reduced leaflet motion is increasingly recognized complication observed in a majority of
TAVR patients even after short time of the implantation. Therefore, the second goal of this
dissertation was to address the issue behind reduced leaflet motion post-TAVR. The study is
aimed to explain the mechanisms behind valvular thrombosis on TAV leaflet surface. The
hypothesis of this study is that since TAV is implanted within the native aortic valve or a
degenerated surgical valve, that increase the chance of blood traps between the TAV outer
surface and the native valve inner surface which increase the likelihood of thrombosis formation
on TAV surface.
PVL is a common clinical complication post TAVR procedure. An accurate evolution of
PVL severity is important for clinical decision. The current methodology to evaluate the severity
of PVL is not validated experimentally, and it shows to over-estimate the severity of PVL.
Accordingly, the third objective of this thesis was to validate the current guideline uses to
evaluate PVL severity and developed a new methodology to assess the severity of PVL post12

TAVR based on fluid dynamics. The introduced approach is based on estimating the maximum
momentum flux of PVL jets, using parameters that are currently being used to estimate the
severity of PVL in clinic.
Energy loss is a well-established engineering concept that applied to evaluate the
performance of native aortic valve and bioprosthetic aortic valve. Energy loss not only allows
assessment of TAV performance during systole, but also allows quantification of PVL during
diastole. The fourth objective of this study is to develop and validate a non-invasive procedure to
estimate the energy loss during the cardiac cycle using doppler echocardiography. Additionally,
energy loss is an excellent parameter to measure workload on the left ventricle due to PVL. In
this study, we quantified the impact of PVL on the left ventricle experimentally.
The general objective of this thesis was to develop a better understanding of the
performance of TAV devices and comparing it with the surgical bioprosthetic which considered
to be the golden treatment option for severe aortic stenosis patients. Additionally, developing and
validating new methods to estimate the severity of PVL following TAVR will save millions of
TAVR patients, and to quantify the overall performance of TAVs during the cardiac cycle.
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Chapter 2: Fluid Dynamics Characterization of Transcatheter Aortic Valves Using
Particle Image Velocimetry
2.1 Introduction
Aortic stenosis due to degenerative calcific aortic valvular disease is the main reason for
aortic valve replacement in developed countries (Kobayashi, Giri, Vallabhajosyula, Herrmann, &
Jagasia, 2015). In developing countries, conversely, rheumatic disease is a common cause of
valvular heart disease (Iung et al., 2003; Organization, 2004). Each year, more than 67 500
surgical aortic valve replacements (SAVRs) are performed in the United States, and over 275 000
are done worldwide (Clark et al., 2012; Rajamannan et al., 2011; Sliwa et al., 2009). The number
of patient with aortic valve disease is expected to triple by 2050 due to aging populations and
high incidence of rheumatic heart disease in developing countries (Association, 2002; Nkomo et
al., 2006; Takkenberg et al., 2008; Yacoub & Takkenberg, 2005). Traditionally, the risks of
lifelong anticoagulation therapy after surgical implantation of mechanical heart valves were
evaluated against the risks of bioprosthetic valve structural deterioration and possible reoperation.
Due to the promising improvements in the long-term durability of surgical bioprostheses,
bioprosthetic heart valves have been recently implanted in more than 90% of patients who are
over sixty years old to avoid lifelong anti-coagulation treatment (De Santo et al., 2012; Egbe et
al., 2015). In addition to SAVR, transcatheter aortic valve replacement (TAVR) has emerged as a
safe and effective alternative treatment option for patients with severe symptomatic aortic
stenosis deemed at high and intermediate risk for SAVR(Adams et al., 2014; Isaacs, Shuhaiber,
Salemi, Isom, & Sedrakyan, 2015; Smith et al., 2011). The possibility of redo transcatheter valvein-valve implantation has also contributed to the shift toward the use of bioprostheses in patient
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(Azadani & Tseng, 2010, 2011; M. B. Leon et al., 2016). Consequently, most patients who
undergo aortic valve replacement currently receive either surgical or transcatheter bioprosthetic
aortic valves.
Unlike surgical stented bioprosthetic heart valves where leaflets are sutured to a frame
mounted on a sewing ring, TAV leaflets are attached to a stent which can be expanded within the
annulus. The lack of a sewing ring in TAVs can lead to a larger valve area compared to surgical
bioprostheses following full expansion of the TAV stent to its nominal size. As a result, clinical
measurements of transvalvular pressure gradients and effective orifice area have been shown that
TAVs match and may even exceed the systolic hemodynamic function of surgical stented
bioprostheses (Daubert et al., 2017; Dvir et al., 2014; Hahn et al., 2013). Although, in-depth
investigation of the flow field structures in TAVs using quantitative measurement techniques
such as particle image velocimetry is of interest to examine the flow-field characteristics (Clavel
et al., 2009; Stühle et al., 2011). In addition, the experimental data provide evidence necessary
for verification and validation of computational models of bioprosthetic heart valves.
Computational modeling and simulations are becoming increasingly accepted component in
design and verification of medical devices in the past few years (Dasi, Simon, Sucosky, &
Yoganathan, 2009). Therefore, the goal of our study was to determine flow field characteristics of
the two commercially available TAV devices, Edwards SAPIEN 3, and Medtronic CoreValve,
during systole and compare it with that of a commonly used surgical bioprosthesis, CarpentierEdwards PERIMOUNT Magna valve, using phase-locked particle image velocimetry (PIV)
measurements.
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2.2 Material and Method
2.2.1 Transcatheter Aortic Valve
Edwards SAPIEN Transcatheter Heart Valve (Edwards Lifesciences) and Medtronic
CoreValve (Medtronic, Minneapolis, MN, USA) have been widely used in clinical trials and
clinical practice. Edwards SAPIEN valve consists of a balloon-expandable stent and bovine
pericardial leaflets. Conversely, Medtronic CoreValve is constructed from a self-expanding
nitinol stent and porcine pericardial leaflets. Both devices were granted CE Mark approval for
commercial use in Europe in 2007. In addition, the U.S. Food and Drug Administration approved
the indication for the systems to include treatment of patients with severe aortic stenosis at high
and intermediate risk for surgery. In this study, detailed flow-field characteristics of 26-mm
Edwards SAPIEN 3 and 26-mm Medtronic CoreValve were determined and compared with that
of a 25-mm surgical Carpentier-Edwards PERIMOUNT Magna aortic heart valve (Edwards
Lifesciences Fig. 1)
2.2.2 Experimental Setup
A custom-built pulse duplicator system (BDC Labs, Wheat Ridge, CO, USA) was used
for testing the three bioprosthetic heart valves (Fig. 2). Heart rate and cardiac output were control
parameters for a virtual LabVIEW pulse-signal-generator that controls a servo pump system.
Each stroke of the pump's piston changes the pressure surrounding a compliant silicone ventricle,
causing ejection through the aortic valve. Custom-made silicone washers (outer diameter 40 mm,
inner diameter labeled size of the bioprostheses, and thickness 10 mm) were employed to mount
the bioprosthetic valves. The Carpentier-Edwards PERIMOUNT Magna bioprosthesis was placed
on the top of the silicone washer and sutures were passed through the sewing ring to hold the
valve in place. In addition, the two TAVs were placed within the custom-made silicone washers,
so that the bottom of the TAV frame (stent) was at the same level as the bottom of the silicone
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washer. A bileaflet mechanical heart valve was placed on the other side of the silicone ventricle
in the mitral valve position. The pulse duplicator input parameters matched the international
standard ISO 5840: 2015 recommendations for testing prosthetic heart valves; that is, heart rate of
70 beats/min, mean atrial and aortic pressures of 10 and 100 mmHg, and cardiac output of 5
L/min. The physiological flow condition was simulated by controlling peripheral resistance in the
pulse duplicator and local compliance using two compliance chambers downstream of the aortic
valve. Recirculating fluid of 45% by volume glycerin solution (99% The Science Company,
Denver, CO, USA) in phosphate buffered normal saline solution (Research Products
International, Mount Prospect, IL, USA) was used as a blood analog fluid. The running solution
has a viscosity of 3.45 cP, a density of 1.12 g/cm3, and a refractive index of 1.39 at 37 °C.
Pressure was measured in the aorta and left ventricle using strain gauge pressure transducers
(Utah Medical Products, Midvale, UT, USA) embedded inside the pulse duplicator 35 mm
upstream and 105 mm downstream of the bio-prostheses. The pressure transducers were
calibrated prior to the tests using Delta-Cal Pressure transducer simulator/tester (Utah Medical
Products, Inc). In addition, an electromagnetic flowmeter (Model 501, Carolina Medical
Electronics Inc, East Bend, NC, USA) was used to measure flow rate in the system. Moreover,
motion of the leaflets was captured using a high-speed camera (Sony DSC-RX10M3) placed on
top of the aortic valve at rates of 480 and 960 frames per second.
2.2.3 Particle Image Velocimetry
A conventional two-dimensional PIV system (TSI, Inc., Shoreview, MN, USA) was used
to obtain planar velocity measurements downstream of the bioprosthetic valves. Illumination was
supplied by a dual oscillator Nd:YAG laser (Litron Lasers Nano S 15 Hz) and lasers were
synchronized using a Laser Pulse Synchronizer (TSI, model 610035, TSI Inc.). Silver coated
hollow glass particles (8 μm diameter, TSI, model 10089-SLVR) were used to visualize the flow.
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Images were recorded with a 1600 × 1200-pixel resolution cross correlation CCD camera (Power
View Plus 2MP, TSI, model 630157), capable of capturing PIV image pairs at 30 frames per
second. For PIV measurement, the camera was fitted to a NIKKOR lens (50 mm f/1.8D) and a
narrow band interference filter was utilized to reduce reflections. The spatial resolution for the
Magna surgical bioprosthesis, CoreValve, and SAPIEN 3 was 58.96 μm/pixel, 62.29 μm/pixel,
and 56.29 μm/pixel, respectively. Phase-locked measurements were acquired by triggering the
PIV system from the pulse generator driving the piston pump, over 91-time instances regularly
spaced over the entire cardiac cycle. All images were correlated on a recursive Nyquist grid using
a 50% overlap with a final pass interrogation window of 24 × 24 pixels. The final interrogation
size was selected to have a careful balance between the highest resolution and the signal-to-noise
ratio of the cross correlations. Data was processed using INSIGHT 3G TM software from TSI.
For simple nondeforming solid boundaries, such as straight pipes, calibration codes can be
applied to the PIV measurements to re-move the optical distortion caused by the refractive index
mismatch between the working fluid and the valve-mounting chamber. For calibration, a plate
with a regular pattern of markers was placed in the field of view along the bioprosthetic
centerline. The image was then used to define the scale and determine the image distortion in
both radial and axial directions. Subsequently, a correction function was determined and a
calibration MATLAB code was applied to the PIV measurements to remove the optical distortion
caused by the mismatch of the refractive index of the working fluid and that of the straight
cylindrical pipe (Stewart et al., 2013). After obtaining the velocity field, Tecplot software
(Tecplot Inc., Bellevue, WA, USA) was adopted to obtain instantaneous viscous shear stress from
the measured 2D velocity gradient using Newton's law of viscosity.
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Figure 2.1: (a) 25-mm surgical Carpentier-Edwards PERIMOUNT Magna bioprosthetic aortic
valve. (b) 26-mm self-expanding Medtronic CoreValve. (c) 26-mm Edward SAPIEN 3
transcatheter heart valve. Adopted from (Vahidkhah, Barakat, et al., 2017).

Figure 2.2: Custom-built pulse duplicator system and PIV setup.
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2.3 Result
2.3.1 Hemodynamics performance of the valves
The raw pressure and flow waveforms obtained from the three bioprosthetic heart valves
in the pulse duplicator are shown in Fig. 2.3. The 25-mm Carpentier-Edwards PERIMOUNT
Magna bioprosthesis had a mean pressure gradient of 8.6 ± 0.07 mm Hg (Fig. 2.3a). In addition,
the effective orifice area of the bioprosthesis was 1.7 ± 0.03 cm2. The effective orifice area was
calculated based on the Gorlin equation. The 26-mm CoreValve, conversely, had a mean pressure
gradient of 7.5 ± 0.16 mm Hg and an effective orifice area of 1.72 ± 0.03 cm2 (Fig. 2.3b). In
addition, the 26-mm SAPIEN 3 had a mean pressure gradient of 6.2 ± 0.052 mm Hg (Fig. 2.3c).
The effective orifice area of the Edwards SAPIEN 3 bioprosthesis was 2.0 ± 0.06 cm2. Moreover,
leaflet motion of the three bioprosthetic heart valves captured by the highspeed camera is shown
in the Supporting Information videos.
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Figure 2.3: In vitro pressure and flow waveforms of (a) 25-mm surgical Carpentier-Edwards
PERIMOUNT Magna bioprosthetic aortic valve, (b) 26-mm self-expanding Medtronic
CoreValve, and (c) 26-mm Edward SAPIEN 3 transcatheter heart valve.
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2.3.2 PIV Results of Surgical valve
Instantaneous velocity vectors and viscous shear stress values of the 25-mm CarpentierEdwards PERIMOUNT Magna bioprosthesis are presented in Fig. 2.4. The time intervals
presented in the figure correspond to five different phases within a cardiac cycle, namely,
acceleration, peak flow, deceleration, early-diastole, and mid-diastole. In the acceleration phase, a
highly axial flow velocity was observed along the bioprosthetic centerline (Fig. 2.4a). At the peak
of flow, a maximum jet velocity of 2.1 m/s was measured in the center of the jet (Fig. 2.4b). The
jet diameter at the peak of flow was approximately 15.2 mm. The velocity decreased abruptly
from the strong central jet to the surrounding region. During deceleration phase, velocity of the
jet at the core was decreased to 1.2 m/s (Fig. 2.4c). Furthermore, significantly lower velocity
magnitudes were observed after the valve closure both in early- and mid-diastole (Fig. 4d,e). In
addition to the velocity field, Fig. 2. 4 demonstrates viscous shear stress fields throughout one
cardiac cycle. At the peak of the flow, maximum viscous shear stress was 4 N/m 2 and occurred
along a significant portion of the jet boundary layer (Fig. 2.4b). During deceleration phase and in
the diastole, however, viscous shear stress was significantly lower than the magnitudes observed
at the peak of the flow (Fig. 4c–e)
2.3.3 PIV Results of CoreValve
Velocity and viscous shear stress fields of the 26-mm Medtronic CoreValve are presented
in Fig. 2.5. During the acceleration phase, as presented in Fig. 2.5a, PIV measurements showed
an accelerating axial flow along the valve centerline. At peak of the systole, a maximum velocity
of 2.2 m/s was measured in the center of the jet (Fig. 2.5b). The diameter of the jet velocity was
approximately 11.3 mm, which was smaller than that of the PERIMOUNT Magna bioprosthesis.
During the deceleration phase, velocity magnitude considerably dropped as shown in Fig. 2.5c. In
addition, even lower velocity magnitudes were observed during the diastole after the valve
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closure. (Fig. 2.5d,e). In addition to the velocity field, Fig. 2.5 illustrates viscous shear stress
magnitude throughout the five phases of one cardiac cycle. At the peak of flow, maximum
viscous shear stress was 4 N/m2 (Fig. 2.5b). However, due to the relatively wider jet boundary
layer in CoreValve compared to the PERIMOUNT Magna valve, the overall magnitude of the
viscous shear stress at the peak of flow was lower in the CoreValve than the PERIMOUNT
Magna bioprosthesis. During the deceleration phase and during diastole, the maximum viscous
shear stress magnitude was significantly lower than the peak of the flow as presented in (Fig.
2.5c–e). Local pockets of elevated viscous shear stress were found within the flow field
downstream of the bioprosthesis
2.3.4 PIV Results of SAPIEN 3
In addition, Fig. 2.6 shows instantaneous velocity vectors and viscous shear stress field of
the 26-mm Edwards SAPIEN 3 bioprosthesis. The first image row shows the acceleration phase,
in which an accelerating axial flow can be clearly observed along the bioprosthetic centerline
(Fig. 2.6a). After 40 ms, at the peak of flow, a strong jet with a maximum velocity of 1.9 m/s was
observed (Fig. 2.6b). The jet diameter was approximately 20.9 mm, which was more than the
Medtronic CoreValve and PERIMOUNT Magna bioprosthesis. During the deceleration phase, as
shown in Fig. 2.6c, velocity of the central jet decreased to 1.3 m/s. Furthermore, significantly
lower velocity magnitudes were observed in the early- and mid-diastole following the closure of
the bioprosthesis (Fig. 2.6d,e). In addition, Fig. 2.6 shows viscous shear stress magnitudes that
were obtained from the velocity field throughout one cardiac cycle. In the peak flow, maximum
viscous shear stress was 4 N/m2 and occurred at the jet boundary layer (Fig. 2.6b). However, the
overall magnitude of the viscous shear stress at the peak of flow within the jet boundary layer was
lower in the SAPIEN 3 than the PERIMOUNT Magna bioprosthesis.
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Figure 2.4: Instantaneous velocity and viscous shear stress fields of 25‐mm surgical Carpentier‐
Edwards PERIMOUNT Magna bioprosthesis in various phases of a cardiac cycle.
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Figure 2.5: Instantaneous velocity and viscous shear stress fields of 26‐mm Medtronic CoreValve
in various phases of a cardiac cycle.
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Figure 2.6: Instantaneous velocity and viscous shear stress fields of 26‐mm Edwards SAPIEN 3
in various phases of a cardiac cycle.
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2.4 Discussion
2.4.1 Summary
In this study, we determined flow field characteristics of the two commercially available
and commonly used TAVs, Edwards SAPIEN 3, and Medtronic CoreValve, using phase-locked
PIV measurements and compared the results with that of a commonly used surgical bioprosthesis,
Carpentier Edwards PERIMOUNT Magna bioprosthesis. The overall systolic hemodynamic
performance of the 26‐mm Medtronic CoreValve and 26‐mm Edwards SAPIEN 3, in terms of the
mean transvalvular pressure gradient and effective orifice area, was slightly superior to that of the
25‐mm Carpentier‐Edwards PERIMOUNT Magna bioprosthesis. The observation was consistent
with the clinical hemodynamic measurements of the bioprostheses (Barakat, Dvir, & Azadani,
2018; Külling et al., 2017). Due to the lack of sewing ring in TAVs, TAV devices offer a larger
orifice area than comparable size surgical bioprostheses after full expansion of the TAV stent to
its nominal size. In addition, the maximum viscous shear stress magnitude within the jet boundary
layer at the peak of the flow was higher in PERIMOUNT Magna than CoreValve and SAPIEN 3
bioprostheses. In addition, the velocity jet diameter was relatively narrower in the Medtronic
CoreValve than SAPIEN 3 and PERIMOUNT Magna, which was due to the conical inflow
section of the CoreValve. The velocity measurements were comparable with majority of previous
studies using 2D PIV to obtain velocity profiles of surgical bioprosthetic valves (Raghav et al.,
2016; Spethmann et al., 2012)
2.4.2 Fluid Dynamics Impact on Thrombotic and Hemolytic
Fluid dynamics has been known to play a critical role in thrombotic and hemolytic
complications associated with prosthetic heart valves (Dasi et al., 2009; Moore & Dasi, 2015).
Thromboembolic events due to hemolysis and shear‐induced platelet activation have been
correlated to high shear stress regions in the blood flow (Becker, Eisenberg, & Turpie, 2001;
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Vahidkhah et al., 2016; Yoganathan, He, & Casey Jones, 2004). The true shear force experienced
by blood cells is caused by viscous shear stress than Reynolds shear stress in the presence of
turbulence (Alemu & Bluestein, 2007; Ge, Dasi, Sotiropoulos, & Yoganathan, 2008). It is well
known that both shear stress magnitude and exposure time are important in activation of blood
cell elements. The higher the exposure time, the lower would be the stress threshold level for
blood cell impairment. The shear stress magnitude of 150 N/m2 is known to be the threshold
under which no red blood cell damage has been observed regardless of the exposure time (Jones,
1995). In the current study, the measured viscous shear stress downstream of the three
bioprostheses was significantly below the threshold level for red blood cell damage reported in
the literature. Conversely, shear‐induced platelet activation occurs at significantly lower shear
stress values. Hung et al in (Leverett, Hellums, Alfrey, & Lynch, 1972) reported platelet damage
at 10–16.5 N/m2 for an exposure time of 102 s, while Williams (Hung, Hochmuth, Joist, &
Sutera, 1976) found a threshold of 13 N/m2 for exposure time levels of 10−3 s. In addition,
Ramstack et al (Williams, 1974) reported platelet activation at a somewhat higher threshold of
30–100 N/m2 with an exposure time of 10−2 – 101 s. The measured shear stress values in the three
bioprosthetic heart valves examined in this study were significantly below platelet activation
threshold reported in the literature. As a result, the predominant mechanism of platelet activation
in the bioprosthetic heart valves will likely be as a result of blood contact with foreign surfaces of
bioprostheses than shear‐induced platelet activation.
2.4.3 Validation of CFD Simulation
In vitro experimental testing has been an integral part of design verification and
optimization of medical devices. In the past few years, the role of computational modeling and
simulations in design and verification of prosthetic heart valves is becoming more and more
important (Ramstack, Zuckerman, & Mockros, 1979). The U.S. Food and Drug Administration
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(FDA) and EU Medical Device Regulatory System are major driving forces behind the trend
(Dwyer et al., 2009; Hsu et al., 2015; Morris et al., 2016; Oberkampf, Trucano, & Hirsch, 2004;
Sirois & Sun, 2011; Stewart et al., 2012). A combined experimental and computational approach
should be considered to shed light on the flow‐mediated mechanisms of thrombosis in
bioprosthetic aortic valves. For instance, regions of blood stagnation provide an opportunity for
platelets and blood proteins to accumulate to critical concentrations leading to thrombosis
(Anning, 1957; Bluestein, Niu, Schoephoerster, & Dewanjee, 1997; Friedrich & Reininger, 1995;
Goodman, Barlow, Crapo, Mohammad, & Solen, 2005; Karino & Goldsmith, 1979; Reininger,
Reininger, Heinzmann, & Wurzinger, 1995; Tan et al., 2012). Contrary to SAVR where native
calcified leaflets are removed from the annulus during open heart surgery, TAVs are implanted
within native valves in TAVR procedures. As a result, the aortic portion of the TAV stent is
circumferentially surrounded by the calcified native valves in TAVR. This configuration is more
pronounced in TAVs that tend to operate inside the annulus such as SAPIEN valves compared to
supra‐annular TAVs such as CoreValve. The geometric confinement of TAVs disturbs the natural
flow field between the leaflets and aortic sinuses, increases the blood residence time (stasis) on
the leaflets, and consequently increases the likelihood of thrombogenesis on the TAV leaflets
(Sukavaneshvar, 2017; Vahidkhah, Abbasi, et al., 2017; Vahidkhah & Azadani, 2017; Vahidkhah,
Barakat, et al., 2017; Vahidkhah, Javani, et al., 2017). Remarkably, leaflet thrombosis is more
commonly observed in TAVR than SAVR (Midha et al., 2017). In addition, the majority of the
reported cases of leaflet thrombosis occurred after using TAVs with intra‐annular design, such as
Edwards SAPIEN and St. Jude Portico valves (Córdoba-Soriano et al., 2015; Mack & Holmes,
2016; Makkar et al., 2015).

29

2.4.4 Study Limitation
In this study, a conventional 2D PIV system was used to obtain planar velocity
measurements downstream of the three bioprosthetic heart valves. In 2D PIV measurements, the
third component of velocity vector cannot be measured. However, since the axial jet velocity is of
such great magnitude during the systole, the third component of the velocity vector is
insignificant. Therefore, the 2D PIV measurements accurately approximate the total viscous shear
stress values in the jet boundary layer during the systole. In the diastole, however, flow is three‐
dimensional, rotational, and spatially inhomogeneous. Therefore, other PIV methods, such as
stereo‐PIV and tomographic‐PIV, should be utilized to measure the three components of velocity
vectors. Another limitation of this study was the lack of aortic sinus and coronary flow in the
pulse duplicator system. However, we believe that the limitations of the currently available in
vitro experimental setups that attempt to model the aortic root geometry justify the use of the
simplified geometry of the present work. For instance, in the currently available pulse duplicator
systems, the aortic root does not represent a patient specific geometry, the root compliance and
coronary arteries are nonexistent, and in the cases that include these properties, the resistance of
coronary arteries cannot be accurately adjusted. As a result, using a simplified geometry
facilitates the validation process of computational works during systole which was one of the
main objectives of this study.
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2.5 Conclusion
A comprehensive evaluation of velocity and viscous shear stress fields downstream of
three commonly used bioprosthetic heart valves was performed using 2D particle image
velocimetry measurements. The in vitro experiments showed that hemodynamic characteristics of
the 26-mm SAPIEN 3 and 26-mm CoreValve were comparable to the 25-mm PERIMOUNT
Magna surgical bioprosthesis. Maximum viscous shear stress was observed at the peak of flow
during the systole within the jet boundary layer in all the three bioprostheses. The measured shear
stress values were below the known threshold for red blood damage and platelet activation.
Therefore, shear‐induced damage to red blood cells and platelet activation are unlikely to take
place during systole in all the three bioprosthesis. Despite the limitations described previously,
PIV measurements can also be used for verification and validation of computational simulation.
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Chapter 3: Valve Thrombosis Post Transcatheter Aortic Valve Replacement: Significance
of blood Stasis on the Leaflets

3.1 Introduction
Transcatheter aortic valve replacement (TAVR) is a promising treatment for patients with
severe aortic valve stenosis whom at high risk of an open-heart surgery. Reduced leaflets motion
due to valvular formation have been increasingly a major complication post TAVR patients (De
Marchena et al., 2015; Egbe et al., 2015; Leetmaa et al., 2015; Makkar et al., 2015). In addition,
reduced leaflets motion has been observed among patients following valve-in-valve (ViV)
procedures (Akhras et al., 2016; De Marchena et al., 2015; Latib et al., 2015; Martí et al., 2015).
Thrombosis formation was mostly found on the surface of the aortic valve leaflets and on the
ventricular surface (Del Trigo et al., 2016; Makkar et al., 2015). Anticoagulation and
antithrombotic therapies are used to prevent thrombosis formation post-TAVR, however a further
investigation is required to determine and manage the mechanisms of thrombosis formation postTAVR. Currently, the management of TAVR depends on history, outcomes, and treatment
responses of SAVR (De Marchena et al., 2015). Thrombosis formation post-SAVR is relatively
low 0.03-1.46% (De Marchena et al., 2015; Egbe et al., 2015; Grunkemeier & Rahimtoola, 1990).
Nevertheless, the assessment of bioprosthetic surgical leaflets motion are not normally done after
SAVR, therefore, the frequency might be underestimated. In contrast to SAVR patients, the
occurrence of reduced leaflets motion due to thrombosis formation among TAVR/ViV may be
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high 40% as reported in a published clinical trial (Brown et al., 2012). The mechanisms beyond
leaflet thrombosis in TAVR/ViV patients still unclear. Therefore, it is important to investigate the
essential factors causing the valvular thrombogenesis post-TAVR/ViV procedure.
In this study, we investigate to address the source of leaflet thrombosis post-TAVR/ViV.
In TAVR/ViV procedures, a transcatheter aortic valves (TAVs) are implanted within the native
calcified aortic valve or a degenerated bioprosthetic valve. Therefore, the aortic stent frame
portion is circumferentially surrounded by the native calcified valve in TAVR setting, or by the
leaflets of the degenerated bioprostheses in ViV setting as it shown in (Fig 3.1). this
implementation configuration is more present with TAVs which tend to place within the annulus
than super-annular TAVS. In this study our theory is that the longer blood resident time (BRT) on
the aortic surface of TAV leaflets because of the annulus surrounded TAV frame, might lead to
explain the high rate of reduced leaflets motion due to thrombosis formation following
TAVR/ViV procedures. Even though the increased of BRT does not result in thrombogenesis by
itself, it suggests that once the clotting process starts, for example by blood contact with the
forgiver surface of TAVs, the likelihood of thrombosis formation increases in the low flow
regions determined by increase BRT (Makkar et al., 2015; Rayz et al., 2010). Blood stasis on the
aortic surface after TAVR/ViV procedures, may be considered as the main reason in thrombosis
formation on the aortic surface. The theory presented in this study is examined by determine BRT
in two different models representing a surgical bioprosthesis and a TAV via statistical analysis.
Additionally, in this study we investigate to quantify the effect of low cardiac output on blood
stasis on the TAV leaflets surface with respect to valvular thrombosis.
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This project is a combination study of computational and experimental technique. A
former postdoctoral Dr. Koohyar Vahidkhah performed the CFD simulation and the calculation
of BRT on the TAV/SAV models. The FE simulation was performed by a former PhD candidate,
Dr. Mostafa Abbasi. On the other hand, I provided with the experimental testing such as
hemodynamics measurements, and PIV results for validating the CFD simulation.
3.2 Material and Method
To investigate the effect of TAVR/ViV setting configuration in intra-annular positioning
on the BRT on TAV leaflets, and the likelihood of thrombosis formation on leaflet, a fluid-solid
interaction (FSI) modeling was used to quantify BRT on TAV leaflets. In this modelling a
computer simulation was performed to mimic the 3-D large deformation of the leaflets along with
the 3-D time-dependent flow field of the bioprosthesis. The input parameters for the simulations,
i.e. transvalvular pressure gradient, was obtained from the pulse duplicator. Additionally,
experimental velocity measurements were used to confirm the validity of the FSI modelling. Due
to the lack of optical access at the base part of TAV, where leaflets are attached to the metallic
frame. Therefore, computer simulations are motivated.
3.2.1 Experimental Setup
A custom-built pulse duplicator system was used to for testing a 23 mm CarpentierEdwards Perimount bioprosthesis to obtain the transvalvular pressure waveform and flow rate.
The pressure waveform and cardiac output were control parameters for a virtual LabVIEW pulse
signal generator that controls a servo pump system. A home-made silicon washer outer diameter
40 mm and inner diameter labeled sized of the bioprosthesis, and a thickness of 10 mm, was used
to mount the bioprosthesis valve. The Carpentier-Edwards Perimount bioprosthesis was places
on top of the silicon washer and sutures were passed through the swing ring. Additionally, a
bileaflet mechanical heart valve was placed in the other side of the silicon chamber. The pulse
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duplicator input parameters matched the international standard ISO 5480:2015 recommendation
for testing prosthetic heart valves, that is, heart rate of 70 BPM, mean arterial and aortic pressure
of 10 and 100 mmHg and cardiac output of 5 L/min. Running fluid of 37 % by volume glycerin
solution (99% the science company, Denver, CO,USA) mixed with normal saline solution
(Research Products International, Mount Prospect, IL, USA) was used as a blood analog solution.
The blood analog solution has the following physical properties: viscosity of 3.8 cp, density of
1.105 g/cm3, refractive index of 1.35.
3.2.2 Validation of FSI Simulation
A 2-D particle image velocimetry (PIV) system was used to obtain the flow field
measurements downstream of the bioprosthesis for validating of simulations flow field. The
lasers were synchronized using laser pulse synchronizer (TSI, model 610035, TSI, Inc.) and the
illumination was supplied by a dual oscillator Nd:YAG laser (Litron Lasers Nano S 15 Hz). The
running solution was seeded with silver coated hollow glass particles (8 μm diameter, TSI, model
10089-SLVR) to visualize the flow. The resolution of the images was 1600 × 1200- pixel cross
correlation CCD camera (power View Pulse 2MP, TSI, model 630157), which can capture PIV
images pairs at 30 frames per second. The spatial resolution for the 23 mm surgical bioprosthesis
was 60 μm/pixel. Phase-locked PIV measurements were performed by synchronizing the PIV
system from the pulse generator driving the piston pump, over 91 images were taken over the
entire cardiac cycle. All images were analysis in Insight 3G TM software from TSI using Nyquist
grid using 50% overlap with a final pass integration window of 28 × 28 pixel. The optical
distraction caused from refractive index mismatching between the running solution and the valve
mounting the chamber, was removed using calibration code. A correction function was
determined and a calibration home-made code was applied to all PIV measurement images to
remove optical distortion and that of the straight cylindrical pipe (Gorbet & Sefton, 2004). The
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velocity field was obtained using Tecplot software (Tecplot Inc., Bellevue, WA, USA) to validate
the velocity field obtained from CFD simulation.
3.2.3 CFD Simulation Steps
The obtained transvalvular pressure gradient from the pulse duplicator was used in a
finite element (FE) simulation to obtain the complex 3-D large motion of the valve leaflets during
the opening and closing of the valve. After that, to calculate the deformation respond of their
assembly to the transvalvular pressure gradient, the large 3-D deformation was divided into
several parts. In this method, the complex deformation of the leaflets was subdivided into several
simpler parts, to calculate the deformation respond of their assembly to the pressure gradient.
After that the deformation motion of the valve leaflets was then input in the computational fluid
dynamics (CFD) model to simulate the complex 3-D flow field of the bioprosthesis. CFD
simulations was performed in two different setups: (1) one representing the surgical bioprosthesis
setup, this one being corresponded to the surgical valve (Fig. 3.1 A) and (2) representing TAVR
setting, this one is being corresponded to TAV model (Fig. 3.1 B). After obtaining the flow field
from the CFD simulation, particle tracking procedure was used to calculate BRT in the valve
leaflets region using a scalar parameter known as (TR). TR can be computed using the equation
below:
𝜕𝑇
𝜕𝑡

+ 𝜈. 𝛻𝑇𝑅 = 1

(1)

3.2.4 Estimating BRT in Patient-Specific Geometry
After validating the BRT approach in models based on the geometry of the pulse
duplicator as in Fig. 3.1, the theory was examined in models was driven from a patient specific
geometry. The anatomical geometry was obtained from computed tomographic (CTA) images of
a 76-years old female with normal aortic root geometry (Fig 3.2A). The geometry of the coronary
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arteries, ascending aorta and aortic root was reconstructed using image processing. In TAVR/ViV
setting, the TAV leaflets are surrounded by frame of failed bioprosthesis valve (Fig. 3.3B, top),
while the TAV leaflets are confined by the native valve’s leaflet as in the intra-annular
positioning (Fig. 3.3B, bottom). TAV leaflets was confined by a cylindrical geometry to reduce
the CFD cost and time.
A FE method was employed to simulate the 3D motion of the leaflets under different
cardiac output, detailed regraded the FE approach can be found in (Barakat et al., 2018). The
obtained large 3D motion of the leaflets during an entire cardiac cycle were used as an input
parameter to the CFD simulation ANSYS Fluent CFD package (ANSYS, Inc., Canonsburg, PA,
USA). The hemodynamic data obtained from the pulse duplicator was used as an input parameter
to the CFD simulation. A 100 mmHg of mean aortic pressure, and 5.0, 3.5, and 2 L/min of
cardiac outputs was used as an impute parameters to the CFD simulation. Additionally, TR was
calculated using Equ 1, to estimate BRT on the valve leaflets.

Figure 3.1: CAD models (A) surgical valve and (B) TAV model .
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Figure 3.2: Patient-specific geometry. (A) 3D patient-specific geometry from CTA images. (B)
TAV leaflets are surrounded by the a failed degenerated bioprosthesis valve as in ViV (top), TAV
leaflets surrounded by the native valve as in TAV (bottom). (C) CFD TAV model.
3.3 Result
3.3.1 Hemodynamics Performance of the Valve
The valvular hemodynamics data was obtained from testing the 23 mm CarpentierEdwards Perimount bioprosthesis in the pulse duplicator. The measured transvalvular pressure
gradient (Fig 3.3) from the experimental test was used as an input dynamic loading in the FE
simulations (Abbasi, Barakat, Vahidkhah, & Azadani, 2016) to obtain valve displacement. The
figure below (Fig 3.4) shows the results of the FE simulations deformation of the bioprosthesis
leaflets during multiple points of the cardiac cycle. An excellent agreement was observed
between leaflet deformation obtained from the FE simulations and the experimental images
captured by the high-speed camera throughout the cardia cycle.
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Figure 3.3: Pressure and flow curves obtained from the pulse duplicator. (A) cardiac output of 2
L/min. (B) cardiac output of 3.5 L/min. (C) cardiac output of 5 L/min.

3.3.2 Validation of FE and CFD Simulation
The results presented in the below figure corresponds to the 23-mm surgical valve, after
obtaining the large 3D deformation of the bioprosthesis leaflets from the FE simulation, it was
used as an input parameter in the CFD model to simulate the flow through the bioprosthesis
valve. A comparison was made between the CFD flow field simulation and the PIV measurement
at the peak of flow, to ensure the validity of the flow in term of flow structure (Fig 3.4(B)). The
presented velocity magnitude contours in Fig 3.4(B) as well as the stream traces during the valve
opening, which were obtained from CFD simulation and PIV experimental measurement, are
illustrated in (Fig. 3.4B(left)) and (Fig. 3.4A(right)). To the reader knowledge, the plane at which
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the velocity contours are presented in (Fig 3.4(B)) was at the mid plane longitudinally cutting
through the bioprosthesis valve. Overall, the above result confirms the validity of the flow
structure in the study.

Figure 3.4: Validation of FE and CFD simulation. (A) Comparison between leaflet motion
captured by the high-speed camera and FE simulation. (B) Comparison between flow field
captured via PIV and CFD simulation at the peak of systole.
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3.3.3 Quantifying BRT in Surgical and Transcatheter Valve During Forward Flow
After confirming the validity of flow field of the two-models which is representing
surgical and TAV valve based on the geometric of the pulse duplicator. Random particles were
generated in the simulated flow field to visualize the effect of the geometric confinement of the
TAV on the BRT on the valve leaflets. The procedure was performed as follows: first, 3000
particles was randomly distributed in the region of interest (ROI). To the reader knowledge the
ROI was defined as the volume between the inner surface of the confining cylinder, which
modeled as the calcified valve or the degenerated bioprosthesis valve, and the outer surface of the
leaflets. In this study the defined ROI illustrates the region in close to the aortic side of the
leaflets. To quantify BRT throughout the opening and closing of the valve, the cardiac cycle was
divided into four stages: I- forward flow, II, closing, III-end of closing to mid diastole, IV-mid
diastole to early systole. Consequently, in the beginning of each phase, the distributed particles
were generated and tracked during the time period. The generated particles follow the flow
velocities and their variation in time throughout the cardiac cycle.
The below figure of the velocity contours of the two models demonstrated the particle
tracking during the forward flow (Stage I). The top raw illustrates the flow field of the surgical
valve in (Fig. 3.5(A)), and that of TAV is illustrated in (Fig.3.5(B)). The contours of the flow
field is shown by the 3D-stream traces and the velocity magnitude contours in the mid-plane of
the CFD domain. The distributed particles are shown in black dot, each black dot showing one
particle. As its clearly to see in (Fig. 3.5), the formation of jet and recirculation areas were similar
between the two models. Additionally, it was easy to notice that the generation of particles was
similar between the two models in the opening stage as it shown in the first three columns.
However, there is a significant difference in the distribution of particles between the two models
in the late stage of forward flow, the last two columns in (Fig 3.5). While its clearly to see that the
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particles were almost washed out of the ROI in the surgical valve model, a significant number of
particles are resided in the ROI on the leaflets of TAV. This result demonstrates the effect of the
confident geometry around TAV on BRT.

Figure 3.5: CFD simulation result showing the distribution of particles during the forward stage.
(A) represent surgical valve. (B) represent TAV model. and the bottom raw indicate the time of
the flow field contours with respect to flow curve.

3.3.4 Quantifying BRT in Surgical and Transcatheter Valve During Valve Closing
The below snapshots of the particle motion during the end of closing to mid diastole (Stage-III),
while the valve is completely closed. The surgical valve is shown in (Fig3.6A), while the velocity
contour of TAV is shown in (Fig. 3.6B). Like Stage-I, a significant difference in the distribution
of particles between the two models, especially at the end of diastole. Again, a considerable
number of particles were noticed to reside on the leaflet in TAV model in the ROI, while most of
the particles were washed away in the surgical valve. Fig 3.6 demonstrates that more particles are
being trapped in TAV model in early and mid-diastole, compare to SAV model.
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3.3.5 Quantify Blood Resident Time in Low Cardiac Cycle.
The same procedure was followed to estimate BRT on the leaflets during low cardiac
output, 3000 imaginary massless particles were randomly generated in the volume of the ROI
between the outer surface of the leaflets and the inner surface of TAV. The distributed particles
have the same velocity magnitude as the simulation. In this part a lagrangian approach was used
to follow and track each particle over time during each stage. The effect of low cardiac output on
BRT on TAV leaflets is shown in (Fig. 3.7), the figure demonstrates contours of time resident of
BRT on the three leaflets during an entire cardiac cycle. During the forward flow, there is no
significant different in BRT among the three cases during the valve opening and closing (the first
three columns) in Fig. 3.7. While, it is observed that BRT was higher mostly at lower cardiac
output during diastole (the last three columns) as in Fig. 3.7. The BRT is high mostly in the fixed
boundary of the three leaflets at lower cardiac output cases especially with cardiac output 3.5
ml/min and 2 ml/min. Blood stasis are not only found in the fixed boundaries of the leaflets,
blood stasis was high in the lesser extent of the free edges. This might be because of the slight
distortion in the leaflet coaptation during diastole in the TAV model.
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Figure 3.6: CFD results demonstrating the particles released in the ROI during stage-III in a
cardiac cycle. (A) Snapshot illustrates particles released downstream of surgical valve. (B)
Snapshot illustrates particles released downstream of TAV.
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Figure 3.7: illustrates the contours of BRT on TAV model leaflets during a whole cardiac cycle.
(A) BRT at cardiac output 5 L/min. (B) cardiac output at 3.5 L/min/ (C) cardiac output at 2
L/min.

3.3.6 Quantifying BRT in two models
Statistical analysis was performed to quantify the differences between the two models in
term of BRT on valve leaflets. The resident time (TR) of the distributed particles in the volume of
ROI, was computed based on the velocity and displacement of the particle in the ROI. The
statistical analysis was calculated after all the particles in all the four stages of an entire cardiac
cycle in the two models computed. The statistical analysis demonstrated that TAV model has
high TR, compared to the surgical model in the four stages (Fig. 3.8). Comparison analysis
between the two models are shown in (Fig. 3.8) included standard deviation which shown as
error bar. As it is observed, the value of TR was 39% higher in TAV model compared to surgical
valve during the forward flow (Stage I). Moreover, TR was even higher during closing (stage II)
132% than surgical valve and was even higher during closing to mid-diastole (Stage III) and mid-

45

diastole to systole (Stage IV). It should be mentioned that a significant difference was noticed
between all cardiac stages in term of TR for both models (P < 0.0005).
In the same way, BRT percentage analysis was performed to quantify the observed
difference in BRT among low cardiac output cases at the end of diastole. In this case the
presented data was defined as S which is the percentage of the total area of the TAV model
leaflets on which blood stasis was noticed to be higher than a selected value. The threshold
values of BRT were chosen as 0.8 to 1.2 s with increment 0.1 s. The selected threshold values
were based on the surface-avenged BRT to the local surface maximum BRT on TAV model
leaflets during the end of diastole in the simulation. The results of the total percentage in term of
S among the three cases of lower cardiac cycles are presented in (Fig. 3.9). As it can be observed,
a significant increase of BRT on TAV model leaflets with low cardiac output cases. The criteria
of TR > 1.2 , the value of S was computed to be 2, 8, and 11% at cardiac output of 5, 3.5, and 2
L/min, respectively. This result illustrates that there is a strong correlation between low cardiac
output and increased blood stasis on TAV leaflets, which could lead to increase the likelihood of
thrombosis formation on leaflets.
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Figure 3.8: Statistical compression average BRT between TAV and surgical models in different
stages of the cardiac cycle. I-forward flow, II-closing, III-end of closing to mid-diastole, IV-mid
diastole to early systole.

Figure 3.9: Evaluation n of the largest BRT areas on TAV leaflets at three different cardiac
output. The vertical axis representing the area of three leaflets on which BRT is higher than
critical values on the horizontal axis.
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3.4. Discussion
3.4.1 Summary
In this chapter, we demonstrated the possibility of thrombosis formation on TAV leaflets
due to the present of confining geometry in TAV, by investigation of BRT on the TAV leaflets.
The CFD results illustrated a significant longer BRT on TAV leaflets, in contrast to surgical
valve during the entire cardiac cycle. the average value of BRT was found to be 39% higher in
TAV model compared to the surgical valve model, during the forward flow. In the same way, the
average of BRT was higher in TAV model compared to surgical model value was 150% and 40$,
respectively, during diastole. The CFD results of this study confirm the validity of the proposed
theory that the geometric confinement of TAV due to native calcified valve or failed
bioprostheses lead to increase of BRT which increase the possibility of thrombosis formation on
TAV leaflets.
3.4.2 Thrombosis Formation post TAVR and SAVR
Generally, the appearance of thrombosis formation post SAVR has been lower than
TAVR procedure, which could be because of neglecting of its awareness. One of the most
reliable tools to investigate the present of thrombosis formation on leaflets and leaflets
immobility are 4-D computed tomographic or transesophageal echocardiographic assessments.
Subclinical thrombosis formation and reduced leaflets motion has been observed post TAVR and
SAVR. A recent published clinical study found that reduced leaflets motion was noticed in 13%
of the patients with either TAVR or SAVR, however in 40% among TAVR patients (Abbasi et
al., 2016). Normally, patients whom underwent with bioprosthetic heart valves are at more risk of
peripheral embolism and stroke than the normal patients. Therefore, the American Heart
Association recommended patients with aortic bioprosthetic valves to take vitamin K antagonists
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(VKAs) for 3-6 months, on the other hand, aspirin is recommended over VKA in European
Society of Cardiology guideline (Makkar et al., 2015; Nishimura et al., 2014).
Flow stagnation and low flow regions in the sinus area has been previously studied due to
blood stasis. For example, a study showed a significant reduced of blood flow in the bases of the
sinus by performing PIV flow measurements (Members et al., 2012). A second published study
reported the effect of TAV positioning on the flow residence time and wall shear stress in the
aortic root (Ducci, Tzamtzis, Mullen, & Burriesci, 2013). Another study addressed the thrombotic
potential by examining the sinus wall shear stress , in different axial positioning in ViV setting
(Groves, Falahatpisheh, Su, & Kheradvar, 2014). However, most of these studies were mainly
focused on the fluid dynamic characteristics in the aortic root. Nevertheless, the association
between the flow stagnation regions in the sinus of aortic root and reduced leaflets motion due to
thrombosis formation still unclear. In this study, the calculation of the BRT was performed in the
defined of ROI, the selected ROI is supported by clinical studies where thrombosis has been
mostly observed (De Marchena et al., 2015; Midha et al., 2015).
3.4.3 Thrombosis Formation in Low Cardiac Output
In this chapter, we demonstrated the effect of low cardiac output on blood stasis post
TAVR procedure, and the likelihood of thrombosis formation due to the present of the
confinement geometry of TAV device. Other hemodynamics parameters could indicate the
present of valvular thrombosis such as aortic regurgitation and transvalvular pressure gradient
(Makkar et al., 2015). However, geometric parameters may affect thrombosis formation on TAV
compared to hemodynamic effects. For example, a study demonstrated the possible link between
TAV size and the increase risk of valvular thrombosis (Chakravarty, Abramowitz, Jilaihawi, &
Makkar, 2016). That encourages a computer simulation to study and address the effect of TAV
geometric on blood stasis on TAV leaflets.
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Some available clinical data suggest a strong relationship between reduced left ventricle
ejection fraction (LFEF) and thrombosis formation after TAVR or ViV procedures. For instance,
a clinical study illustrated the possible association between low LVEF (<35%) and thrombosis
formation post TAVR (Hansson et al., 2016). In the same way, a recent clinical observation has
pointed out to a significant correlation between low ejection fraction and the predication of
leaflet thrombosis (Leetmaa et al., 2015). However, another clinical data reported that an LVEF
of <35% is not sufficient to predicate leaflet thrombosis . The CFD results of this study show a
significant correlation between low cardiac output and leaflet thrombosis. The presented data
might help to demonstrate the apparent of leaflet thrombosis in the clinical data. In this study we
proved that cardiac output is an appropriate factor to address the likelihood of leaflet thrombosis
compared to LVEF.
3.4.4 Study Limitation
This chapter is a combination of computational studies and experimental testing
environment which can be used to validate the computer simulation results. One of the limitations
of this study is the absent of the aortic root geometry in the model, however in the current study
the determine of the ROI was realistic condition, therefore our hypothesis is not affected by the
geometric simplification. Geometric details such as TAV stent, calcified native valve and
bioprosthetic frame or failed bioprosthetic valve around the stent were missing in this work
which consider a second limitation, however the presented hypothesis mostly focus on quantify
and comparison of the BRT between the surgical and TAV models, therefore the results remain
valid, though the absent of the geometric details. Even with all the listed limitation, the defective
washout of blood from bioprosthetic leaflet is unbelievable to change or vary by defining more
details to the models.
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3.5 Conclusion
In short, the results of this study demonstrate that flow field in TAVR leaflets disrupted
because of the geometric confinement resulted from calcified native valve or degenerated
bioprosthesis that circumferentially around the TAV, as opposed to SAVR. Additionally, there is
a significant association between low cardiac output and increased BRT which can increase the
likelihood of thrombosis formation on TAV leaflets. Areas of low blood flow could lead to
valvular thrombosis by accumulating platelets and blood proteins to a critical concentration.
Furthermore, the presented geometric confinement in TAV causes to longer BRT which lead to
leaflets thrombosis. The above results support many clinical observations on reduced leaflet
motion due to valvular thrombosis following TAVR and ViV procedures. The presented results
suggest further investigations regarding geometric variability associated with TAVR and ViV
procedures in term of TAV type, size and positioning.
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Chapter 4: Assessment of Paravalvular Leakage Post Transcatheter Aortic Valve
Replacement: A New Approach Based on Maximum Momentum Flux

4.1 Introduction
Previously, TAVR was a limited treatment option for patients whom are at high risk of
open-heart surgery. Recently the U.S. Food and Drug Administration (FDA) approved TAVR
regardless of patient’s surgical risk (Chakravarty et al., 2017; Coylewright et al., 2020). In
contrary to SAVR, where surgeons remove the calcified valve and replace it with a bioprosthetic
valve, in TAVR procedure transcatheter aortic valves (TAVs) are implanted within native or a
degenerated bioprosthetic valve. As a result of TAVR procedure, paravalvular leakage (PVL) is a
frequent complication among TAVR patients (Coylewright et al., 2020; Neragi-Miandoab &
Michler, 2013; Webb et al., 2007). There is growing evidence suggesting a significant association
of PVL, even mild, with short and long-term mortality (Grube et al., 2007). The incidence of mild
PVL post TAVR is still quite significant with the third generation of TAVR devices (Kodali et
al., 2012). A clinical study has reported the severity of PVL post TAVR was 32% mild, 40%
moderate and 17% severe (Chakos et al., 2017). Nevertheless, there is a lack of validated protocol
to evaluate PVL post TAVR and ensure the appropriate classification of its severity.
Accurate evaluation of PVL is essential for clinical decisions. The current TAVs device
provides superior systolic performance in terms of hemodynamics performance (Barakat et al.,
2018; Gotzmann et al., 2011; Walther & Falk, 2009). However, measuring the regurgitation
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volume (RV) of PVL is considered to be the most accurate way to evaluate the severity of PVL,
the current guideline concludes that an RV of <30 ml/beat, 30-59 ml/beat and <60 ml/beat
corresponds to mild, moderate and severe, respectively (Clavel et al., 2009; Zoghbi et al., 2009).
Nevertheless, measuring RV in patients can be performed using MRI, however it’s not accurate
and costly. On the other hand, the circumferential extent (CE) of PVL has been introduced by the
Valve Academic Research Consortium II (VARC II) as a semi-quantitative method to classify the
severity of PVL post TAVR (Kappetein et al., 2012; Lang et al., 2005). This method depends on
capturing careful imaging of the paravalvular jet in a short axis view, at the level of the TAVs
using two-dimensional echocardiograph (Bloomfield et al., 2012). Although the CE has not been
validated, it has been widely used to estimate the severity of PVL. According to this method a CE
of 10-29% suggests to moderate PVL, less than 10 % corresponds to mild PVL and larger than
29% of PVL suggests to severe PVL (Kappetein et al., 2012). Additionally, totally depending on
short axis echocardiography images, often can be limited and misleading due to the present of
multiple PVL jets that are not parallel to the echo probe (Pibarot, Hahn, Weissman, & Monaghan,
2015). In this study, we first validate the CE of PVL, and then propose a new novel approach
based on fluid dynamics concept to assess the severity of PVL. The proposed method is based on
the estimation of the maximum momentum flux at the vena contracta of the leakage jet flow using
parameters that are currently being used for PVL classification, i.e. maximum jet velocity, CE of
PVL, and the aortic and ventricular pressures. The validation of CE and estimation of maximum
momentum flux was achieved via computational flow dynamics (CFD) modeling and in vitro
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This study is a combination work of CFD modeling and experimental approach. To
ensure the feasibility of the proposed approach, first a CFD model was developed to estimate the
CE in correspond to multiple level of PVL severity at steady flow condition. After that, the
maximum momentum flux was estimate. After ensuring the feasibility of our new approach, an in
vitro study was performed to measure and estimate the CE and maximum momentum flux,
respectively under a pulsatile flow condition. The CFD simulation was performed by a former
postdoctoral Dr. Koohyar Vahidkhah. I conducted the experimental testing which was used to
validate the CFD modeling.
4.2 Material and Method
4.2.1 Theoretical Background
In this study we present a simple approach based on fluid dynamics concept to estimate
maximum momentum flux in PVL using parameters that are recommended by VARC-II to assess
the severity of PVL post-TVAR. The parameters we introduce to estimate the maximum
momentum flux, are being currently used to estimate the severity of PVL, such as maximum
velocity jet, CE of the jet, and the aortic and ventricular pressures of the PVL. The schematic
layout in Fig. 4.1 demonstrates the location and the procedure of presented approach. In (Fig.
4.1a) is a CFD snapshot showing the locations of where these parameters were measured, while
in (Fig. 4.1b) a flowchart demonstrates the overall procedure to estimate the maximum
momentum flux at the vena contracta. The following calculation steps were performed in in
vitro and in CFD simulation results:
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Bernoullie equation was used to estimate the pressure at the vena contracta (𝑃𝑣𝑐 ). The equation
was applied between aortic and vena contracta as in (Fig. 4.1a), assuming the difference height as
well as the head loss are negligible.
𝑃𝐴

=
𝜌𝑔

𝑃𝑣𝑐

𝑉2

𝑣𝑐
+ 2𝑔
𝜌𝑔

(1)

By using Eq. 1, the pressure at the vena contracta can be estimated as 𝑃𝑣𝑐 = 𝑃𝐴 −

2
𝜌𝑉𝑣𝑐

2

.

Where (𝑉𝑣𝑐 ) is the maximum velocity of the PVL which is measured using Doppler CW long axis
view, while 𝑃𝐴 is measured in the pulse duplicator. Once 𝑃𝑣𝑐 is found, the following

momentum equation balance was applied between vena contracta and left ventricle:
2
𝑃𝑣𝑐 𝐴𝑣𝑐 + 𝜌𝑉𝑣𝑐2 𝐴𝑣𝑐 = 𝑃𝐿𝑉𝑂𝑇 𝐴𝐿𝑉𝑂𝑇 + 𝜌𝑉𝐿𝑉𝑂𝑇
𝐴𝐿𝑉𝑂𝑇

(2)

In Eq. 2 the viscous loss due to duct walls were neglected since we are measuring
maximum momentum flux which is at the vena contracta. (𝑃𝐿𝑉𝑂𝑇 ) represents the LVOT pressure
which is measured in the pulse duplicator. On the other hand, (𝐴𝐿𝑉𝑂𝑇 ) is estimated using images
taken by color doppler from short axis view. Additionally, (𝑉𝐿𝑉𝑂𝑇 ) is measured using Doppler
PW from long axis view at the location where 𝐴𝐿𝑉𝑂𝑇 were estimated. Having the values of
pressure and velocity at the vena contracta with the surface area at the exit of the jet, the area of
2
)⁄(𝑃𝑣𝑐 + 𝜌𝑉𝑣𝑐2 )
vena contracta can be estimated by using Eq. 2 𝐴𝑣𝑐 = 𝐴𝐿𝑉𝑂𝑇 (𝑃𝐿𝑉𝑂𝑇 + 𝜌𝑉𝐿𝑉𝑂𝑇

The estimated values of A_vc can then be used to estimate the maximum momentum flux of the
PVL 𝐽𝑚𝑎𝑥 = 𝜌𝑉𝑣𝑐2 𝐴𝑣𝑐 .
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Figure 4.1 (a) Schematic of the idealized flow simulation model for PVL. (b) Overview of the
proposed approach for the assessment of the severity of PVL regurgitation.

The proposed method is summarized as follows:
𝜌𝑉 2

1- Estimate the pressure at the Vena Contracta: 𝑃𝑣𝑐 = 𝑃𝐴 − 2𝑣𝑐. Note that the values of 𝑃𝐴
comes from the pulse duplicator, and 𝑉𝑣𝑐 comes from long-axis CW measurement.
2- Estimate the surface area of high velocity regions at TAV color Doppler short-axis plane
𝐴𝐿𝑉𝑂𝑇 in the LVOT region.
3- Estimate the velocity at 𝐴𝐿𝑉𝑂𝑇 from long-axis view PW measurement 𝑉𝐿𝑉𝑂𝑇 .
2
)⁄(𝑃𝑣𝑐 + 𝜌𝑉𝑣𝑐2 ).
4- Estimate the area of vena contracta from 𝐴𝑣𝑐 = 𝐴𝐿𝑉𝑂𝑇 (𝑃𝐿𝑉𝑂𝑇 + 𝜌𝑉𝐿𝑉𝑂𝑇

5- Estimate the maximum momentum flux of PVL using 𝐽𝑚𝑎𝑥 = 𝜌𝑉𝑣𝑐2 𝐴𝑣𝑐 .

4.2.2 CFD Simulation of PVL
The geometry of the flow simulation was obtained from a de-identified computed
tomographic angiography (CTA) images of a 76-year-old female see (Fig. 4.2a). The geometry of
the left ventricle, aortic root, ascending aorta, and the coronary arteries was then reconstructed
using an image processing package (ScanIP; Simpleware Ltd., Exeter, UK). Once the patient
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specific geometry was obtained, a model representing PVL was developed. The PVL was
modeled by introducing gaps between the TAV geometry and the native valve commissures as its
seen in (Fig. 4.2b). The level of the leakage was adjusted by the curves that represented the free
edges of the native valve leaflets at the commissures.

Figure 4.2 (a) Construction of the 3D patient-specific geometry via processing of CTA images.
(b) Computational 3D model for the TAV.

The geometry generated for each PVL case was discretized by unstructured tetrahedron
cells using ANSYS Meshing. The mesh was refined near of the aortic valve, where large pressure
gradients were expected. The PVL flow was generated by prescribing an average aortic pressure
of 76.5 mmHg and an average ventricular pressure of 5.0 mmHg to the boundary surfaces of the
computational domain. The above choice of pressure values was based on time-averaging the
transient aortic and ventricular pressures during diastole. Similarly, at the coronary artery outlets,
the average pressure was prescribed based on normal phasic coronary blood flow. The use of
time-averaged pressure boundary conditions allowed steady-state simulations and consequently
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reduced computational cost and time. In addition, a standard k-ε turbulent model with standard
wall functions were employed for the flow simulations. No-slip boundary conditions were applied
to the surrounding wall, valve frame and leaflets, as well as the TAV confining geometry. A
second-order implicit transient formulation was utilized to solve the conservation equations. The
density and the viscosity of blood were 1060.0 kg/m3 and 0.0035 kg.s/m2, respectively.
4.2.3 Fabrication of PVL and Valve Models
Clinically, most of PVL cases accrue near or at the TAV’s commissure as it shown in
Fig. 4.3 (a-b) (Zamorano et al., 2011). Therefore, to model PVL in vitro, a custom-built 3D
printed washer was used by introducing three anatomically realistic gaps between the TAV
geometry and the native valve commissures as it shown in Fig. 4.3 (c). Additionally, a 26 mm
SAPIEN 3 Transcatheter Heart Valve (Edwards Lifesciences) was implemented within the 3D
printed washer as in Fig. 4.3 (c), was placed at the aortic position. The SAPIEN 3 was not fully
expanded to its labeled diameter, for a potential higher-pressure gradient than normal. Also, a
bileaflet mechanical heart valve was placed at the mitral position. The flow through the gaps are
driven by contraction from the aortic side followed by duct entrance and exiting into the left
ventricle chamber. The jet flow inside the duct is driven from the pressure gradient between the
aorta and the left ventricle. The jet reaches its maximum velocity at the vena contracta which
occurs at the entrance of the duct. After the jet exits the duct, the flow is confined by the left
ventricle outflow tract (LVOT) geometry and the left ventricle chamber. The stages of PVL
severity was controlled by increasing and decreasing the circumference of the gaps, however, the
gap width was kept at 2 mm. The 3D printed washer has an outer diameter of 40 mm, and an
inner diameter of the TAV 22 mm, and height of 16 mm.
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Figure 4.3. (a) TAVR implanted on calcified valve, the white arrows show the TAV’s
commissure. (b) Show the bottom view of TAV. (c) SAPIEN 3 TAV implanted in the 3D-printed
washer, the black arrows show the gaps facing the valve’s commissure.

4.2.4 Experimental setup
An in vitro study provides a consistent and well-controlled environment to assess and
quantify the severity of PVL. A custom-built pulse duplicator (BDC Labs, Wheat Ridge, CO,
USA) was used for testing, as previously illustrated (Litzler et al., 2008). The image of the
experimental setup and diagram layout are presented in (Fig. 4.4a-b). The pulse duplicator
consists of silicon ventricle chamber pressurized in a water tank. The system generates
physiological flow condition by pulsatile pump. Additionally, the pulse duplicator input
parameters matched the international standard ISO 5840:2015 recommendations for testing
prosthetic heart valves; that is, heart rate of 70 beats/min, and cardiac output of 5 L/min. The
mean aortic pressure was set to 100 mmHg first and then to 120 mmHg to generate wide range of
data measurements of PVL severity for patients with normal and high mild hypotension.
Recirculating fluid of 36% by volume glycerin solution (99% The Science Company, Denver,
CO, USA) in phosphate buffered normal saline solution (Research Products International, Mount
Prospect, IL, USA) was used as a blood analog fluid. The blood analog solution contained Silver
coated hollow glass particles (8 µm diameter, TSI, model 10089-SLVR). Additionally, the
running solution has a viscosity of 3.6 cP, a density of 1.102 g/cm3 at room temperature. Pressure
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was measured in the aorta and left ventricle chamber using strain gauge pressure transducers
(Utah Medical Products, Midvale, UT, USA). Static pressure measurement was taken at 105 mm
downstream and 35 upstream of the aortic and left ventricle, respectively. Moreover, pressure
transducers were calibrated prior to the tests using Delta-Cal Pressure transducer simulator/tester
(Utah Medical Products, Inc). In addition, an electromagnetic flowmeter (Model 501, Carolina
Medical Electronics Inc, East Bend, NC, USA) was located on top of the aortic valve and used to
measure the regurgitation mass flow rate of the RV in the system as it shown in (Fig. 4.4b).
4.2.5 Doppler Measurements
Doppler echocardiography measurements were perform using iE33 ultrasound system
(Philips Medical Systems, Andover, Massachusetts) and a V219 (2.5 MHz) was steadily placed at
the bottom and the side of the pulse duplicator tank as it shown in (Fig. 4.4b). The Doppler
measurements were performed based on the current recommendation and guidelines (Barakat et
al., 2018; Lang et al., 2005) ] for evaluating the severity of PVL. Velocity measurement was
performed by placing the probe beam at the bottom of the pulse duplicator tank see (Fig. 4.4b).
The velocity at the vena contracta was measured along the jets using continuous wave Doppler
(CW) from long axis as it seen in (Fig. 4.4b). Furthermore, pulse wave (PW) were used to
measure velocity at the exit of the jets in the LVOT region. Area of the jets were taken using
color Doppler from short axis view by placing the probe beam on the side of the water tank (Fig.
4.4b). Color Doppler was performed right below at the bottom of the TAV’s level, and at the
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location where PW velocity was measured using short axis as it’s shown in Fig 3(b). Moreover,
three cardiac cycles were captured for all echocardiography results.

Figure 4.4. (a) Pulse duplicator system with valves positioned within the system. (b) Diagram
layout of the experiment setup.
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4.3 Results
4.3.1 CFD Steady Validation of Circumferential Extent
The CFD results in (Fig. 4.5a-c) demonstrates a sample of the short axis view from the
CFD simulation with RV of 47.7 ml/beat. The velocity contours in (Fig. 4.5a-b) are shown at the
bottom plane of the SAPIEN 3 at which the echocardiography views are obtained to evaluate the
severity of PVL. As it shown in (Fig. 4.5b), for evaluation the PVL, the contours of velocity
magnitude must be ideally viewed at the TAV plane short axis view; i.e. the plane that
encompasses the lowest circular curve of the TAV stent and the Dacron at the ventricular side.
On the other hand, in (Fig. 5c), a stream traces are colored by the fluid velocity magnitude to
visualize the flow view on a plane that longitudinally along the PVL jet at the leakage origin. The
PVL severity in each simulation was determined directly by calculating the RV from the flow
velocities at the computational outflow. After obtaining the accurate PVL severity from the
calculated RV in each case, the accuracy of the PVL assessment by the CE of PVL can be
validated.

Figure 4.5. CFD results simulation of paravalvular leakage. (a,b) The corresponding contours of
flow velocity magnitude of PVL from short axis view. (c) Long axis view velocity flow contours
of PVL jet.
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The CE of PVL is visually estimated as the percentage of the perimeter of the TAV
occupied by high flow velocity regions in the short-axis view. (Fig. 4.5b) demonstrates how CE
of PVR was estimated in the simulations, the total length of the dashed lines is calculated and
divided by the TAV perimeter. According to the guidelines (Baumgartner et al., 2009; Zamorano
et al., 2011) a CE of PVL of 10-29%
Corresponds to medium PVL, and values smaller than 10% and larger than 30%
correspond to mild and severe PVL, respectively. The semi-quantitative parameters for the
assessment of AR severity, i.e. CE of PVL, were calculated for each simulation. Table 1 shows
sample results of CE of the PVL of which spans mild, medium, and severe grades of PVL, along
with their corresponding semi-quantitative assessment. The estimated severities are shown in
green color for the cases in which the assessment was accurate and in red for those in which the
assessment was erroneous. As it is observed, in a considerable number of cases, the semiquantitative assessment of PVL severity failed to produce accurate predictions. More specifically,
the CE of PVL was observed to over-predict the severity of PVL for mild and moderate cases. On
the other hand, the CE shows to give a good estimation among the severe cases.
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Table 4.1. Semi-quantitate assessment of PVL severity
RV
(ml/beat)

Paravalvular
Leakage

Actual
Severity

Circ. Extent of
PVL(%)

Severity based on
Circ.Extent of PVL

14.6

Mild

22

Moderate

17.6

Mild

29

Moderate

30.2

Moderate

37

Severe

39.4

Moderate

30

Severe

47.7

Moderate

38

Severe

54.3

Moderate

38

Severe

60.2

Severe

43

Severe

63.8

Severe

47

Severe

A linear correlation shown in (Fig. 4.6) demonstrates the variation in the estimated CE of
the PVL and the calculated RV in the simulation. As its evident from the R2 in the plot, a poor
correlation was found between CE and RV. The plot illustrates an over predication of the severity
of PVL among the mild cases especially, however, the linear correlation can be seen among the
moderate/severe and severe cases. The simulation demonstrates a new critical value of CE, i.e CE
= 24 and CE = 47, can be defined as mild/moderate and moderate/severe boundary values. Note,
the presented data in (Fig. 4.6) corresponds to average aortic pressure of 76.5 mmHg and left
vertical pressure of 5 mmHg.
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Figure 4.6: Linear correlation between the calculated RV and the estimated CE of the PVL in the
CFD simulation.

The above observation highlights the requirement for quantitative assessment of PVL
severity. Evidently, an ideal approach would be a comprehensive computer simulation that
encompasses all the biophysical phenomena and the geometric details of the case under
consideration to predict the RV accurately. However, since such computer simulation would
involve time-consuming and costly processes such as the generation of the complex 3D geometry
from CTA images and the CFD simulation of flow field, this study aims to propose an alternative
approach that in terms of complexity, accuracy, and cost lies between the two ends, one being the
semi-quantitative assessment and one accurate computer simulation. The main goal of the CFD
approach is to assess in the validation of the CE of PVL, before developing the experimental
setup. The proposed method is simple and is based on fluid mechanics concepts, specifically the
momentum flux of the leakage.
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4.3.2 Estimating Maximum Momentum Flux using CFD Simulation
After estimating the CE of PVL, the momentum flux of the leakage jets was calculated in
each simulation. The momentum flux was calculated in the TAV plane as well as parallel planes
that span across the TAV height. It was observed that a significant variation in the calculated
momentum flux along the jets, due to the geometric confined of TAV stent and Dacron on one
side and the aortic root on the other side. The jet flow in the PVL is more like a duct flow in
which the duct cross section varies along the flow direction. The contractions and expansions of
the duct cross section lead to increase and decrease in the leakage momentum flux, respectively.
As shown in (Fig.4.1a), the flow of PVL is modeled by a contraction from the aortic side (Fig.
4.1a) to a duct entrance followed by a duct flow (Fig. 4.1a). The pressure difference between the
aortic and the ventricular side drives the fluid into the duct-like chamber where it reaches its
maximum velocity at the Vena Contracta (Fig. 4.1a); then the flow is confined by the TAV and
aortic root geometry and it pressure/velocity varies based on the variations in the cross section of
the duct.
The pressure at the vena contracta is calculated by using Equ. (1), the aortic pressure PA
is known as an input parameter for the CFD model, while the maximum velocity Vvc is obtained
by measuring the velocity right at the inlet of the duct from the CFD results. The area of the
LVOT region ALVOT is found by calculating TAV areas that are occupied by high velocity regions
as shown in (Fig. 4.5a). Additionally, the velocity VLVOT is measured as 80% of the maximum
velocity magnitude from the simulation, assuming the duct flow by a turbulent pipe flow with a
relative low Reynold number (~4000). Having the values of pressure, velocity and surface area at
the LVOT, the unknown value of Avc can be calculated using Equ. 2, the ventricle pressure of the
CFD simulation can be used as PLVOT . After calculating the area of the vena contracta, the value
of the maximum momentum flux of the leakage can be calculate.
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Table 2 demonstrates the results for the assessment of the PVL severity using the newly proposed
approach. As it is observed the new method offers significant improvements in terms of accuracy
compared to the commonly used semi-quantitative method which was previously presented in
Table 1. Additionally, (Fig. 4.7) demonstrates the variations in the maximum value of momentum
flux, 𝐽𝑚𝑎𝑥 , with the RV in the CFD simulation. As it is evident from the value of R2 in the plot, a
linear correlation exists between 𝐽𝑚𝑎𝑥 and the calculated RV. The plot shows that there exists a
one-to-one correspondence between the regurgitant volume of a valvular leakage and its
maximum momentum flux. This indicates that the maximum momentum flux, 𝐽𝑚𝑎𝑥 , can be
effectively used to assess the severity of the valvular leakage. As shown in (Fig. 4.7), two critical
values of 𝐽𝑚𝑎𝑥 , i.e. 𝐽𝑐𝑟𝑖𝑡,1 = 0.8 and 𝐽𝑐𝑟𝑖𝑡,1 = 1.57, can be defined as the mild/moderate and
moderate/severe boundary values.

Table 4.2. Assessment of PVL severity by the newly proposed approach

Paravalvular
Leakage

RV
(ml/beat)
11.7
14.6
17.6
30.2
39.4
47.7
54.3
60.2
63.8

Actual Severity
Mild
Mild
Mild
Moderate
Moderate
Moderate
Moderate
Severe
Severe
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Estimated Jmax
(N)
0.50
0.21
0.38
0.68
0.89
1.09
1.44
1.59
1.76

Severity Baes on
Jmax
Mild
Mild
Mild
Mild
Moderate
Moderate
Moderate
Severe
Severe

Figure 4.7: Linear Correlation between the calculated RV and the maximum momentum flux of
the leakage jets.

The goal of the CFD modeling was to confirm the proposed steps in section (4.2.1) and
ensure the validity of neglecting viscous loss throughout the duct. The amount of maximum
momentum flux remains relatively constant past the duct under steady condition. This
observation increased the desire to develop an experimental testing to compute the maximum
momentum flux under pulsatile condition.
4.3.3 Estimating CE Experimentally.
In this study, first we validated the CE which is the most common method used to
clinically methodology to evaluate the severity of PVL post-TAVR. The CE of PVL was
estimated at 100 and 120 mmHg of mean aortic pressure. The short axis results of the color
Doppler in (Fig. 4.8 a-c) demonstrate multiple cases of PVL severity in the present of multiple
jets. The color Doppler images were taken at the neck of the leakage jet, right at the bottom plan
of the SAPIEN 3 valve. The CE of PVL is visually estimated as the circumference of the
perimeter of the TAV occupied by high flow velocity regions with respect to the total
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circumference of the TAV bottom plane. The color Doppler image in (Fig. 4.8a) corresponds to a
mild case with a RV of 11.46 ml/beat and a CE of 14.64 %. On the other hand, the color Doppler
image in (Fig. 4.8b) corresponds to moderate case with RV of 35.74 ml/beat, and 35.21 % of the
CE. The short axis image in (Fig 4.8c) corresponds to a severe case with RV of 60.25 ml/beat,
and CE of 45.49%.

Figure
4.8: In vitro color Doppler images of multiple degrees of PVL severity were taken from the short
axis view. (a) Shows results RV of 11.46 ml/beat. (b) Shows results RV of 35.74 ml/beat. (c)
Shows results RV of 60.25 ml/beat

The plot in Fig. 4.9 demonstrates variations between the estimated CE with the measured
RV, solid circles and empty diamond indicate to 100 and 120 mmHg of mean aortic pressure,
respectively. The in vitro results of the estimated CE show poor correlation between the measured
RV experimentally and the estimated CE, as its evident from the value of R2 in the plot.
Moreover, the plot indicates that a CE smaller than 24% corresponds to mild PVL, a CE bigger
than 48% corresponds to severe PVL and a CE between 24%-48% corresponds moderate.
Additionally, the semi-quantitative assessment of PVL severity failed to predicate the severity of
PVL accurately. More specific, the CE of PVL was observed to over-predicate the severity of
PVL for mild and moderate cases, in fact the plot shows a better correlation between RV and CE
among severe cases comparing to mild and moderate cases. The in vitro results of CE confirm
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the validity of the CFD simulation results. Additionally, it was noticed that there is no significant
impact on the estimated CE from increasing aortic pressure.

Figure 4.9: Linear correlation between the measured RV and the estimated CE obtained from the
in vitro measurements.
4.3.4 Maximum Momentum Flux In Vitro
To confirm the validity of the echocardiographic parameters that were used in the new
proposed method, a statistical analysis of these parameters is demonstrated in Table 4.3 at 100
and 120 mmHg of mean aortic pressure. It was observed that the measured pressure in the left
ventricular increased with respect to the severity of PVL at 100 and 120 mmHg, while no change
within the measured pressure in the aorta for all cases. However, left ventricular pressure
increased dramatically with increasing aortic pressure Another thing that was noticed is the
pressure gradient between aorta and left ventricle was decreased correspond to the level of
severity, additionally, pressure gradient increases with increasing aortic pressure and it decreases
with respect to the severity level. Moreover, the measured maximum velocity decreases with
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respect the severity of PVL. Maximum velocity magnitude increases with increasing aortic
pressure as it illustrated in Table 4.3.
Table 4.3: Hemodynamics measurements from the in vitro testing with different level of severity

The maximum momentum flux of the leakage jets was calculated at 100 and 120 mmHg
of mean aortic pressure. The estimated momentum flux was calculated with respect to the vena
contracta of the duct flow which corresponds to detect the maximum forces presenting in the duct
flow. The echocardiographic images in (Fig. 4.10) are sample with different level of PVL
severity, those images were used to estimate parameters that used to calculate momentum flux in
the leakage jets. In Fig. 4.10a demonstrates a mild case with RV of 13.60 ml/beat, Fig. 4.10b
shows a moderate case with RV of 46.65 ml/beat and Fig. 4.10b shows a severe case with RV of
64.32 ml/beat. The color doppler images (Fig 4.10) were used to estimate the area at the LVOT
region, image processing was performed to calculate the area of the TAV high velocity occupied
areas. The middle raw in Fig. 4.10 demonstrates pulse wave velocity measurement from long axis
view, the blue arrow indicates systole while the red arrow indicates diastole. A caliper tool in
echocardiography was used to measure velocity at the LVOT region, PW measurements at the
LVOT region. The bottom raw in Fig. 4.10 illustrates maximum velocity of the leakage jets was
captured using CW doppler, which corresponds to the velocity at the vena contracta. Velocity
time integral (VIT) was used to measure the average maximum velocity magnitude along the jets.
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Figure 4.10: A sample of echocardiographic obtained from different level of PVL severity. (a) a
mild case with RV of 13.60 ml/beat. (b) a moderate case of 46.65 ml/beat. (c) a severe case of
64.32 ml/beat. The first top raw shows color doppler of the LVOT area. The middle raw shows
pulse wave velocity images at the LVOT area. The bottom raw shows continuous wave of the
velocity magnitude at the vena contracta.

The plot in Fig. 4.11 demonstrates linear correlation between the measured RV and the
calculated momentum flux, the solid circles presents data of 100 mmHg while empty diamonds
presents data of 120 mmHg. A significant linear correlation exists between RV and momentum
flux, as it is evident from the R2. The plot in Fig. 4.11 shows that there exists a one-to-one
correspondence between the measured RV of a PVL and its maximum momentum flux. This
indicates that the maximum momentum flux, 𝐽𝑚𝑎𝑥 , can be used to estimate the severity of PVL.
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As shown in Fig. 4.11 two critical values of 𝐽𝑚𝑎𝑥 , i.e. 𝐽𝑐𝑟𝑖𝑡,1 = 1 and 𝐽𝑐𝑟𝑖𝑡,2 = 2, can be defined
as the mild/moderate and moderate/severe boundary values. Furthermore, it was observed there is
no significant impact on momentum flux from increasing of aortic pressure as it shown in Fig.
4.11.

Figure 4.11: Correlation between regurgitant volume (RV) and the maximum momentum flux of
PVL. Empty diamond corresponds to mean aortic pressure of 120 mmHg. Filled circles
correspond to mean aortic pressure of 100 mmHg.

4.4 Discussion
4.4.1 Summary
Due to the natural of TAVR implantation procedure, PVL is one of the most common
clinical issues associated with TAVs devices. The severity of PVL was graded as mild, moderate
and severe according to the American Society of Echocardiography recommendation for
evaluation native (Zoghbi et al., 2009). Measuring the amount of PVL per beat is the accurate
way to evaluate the severity of PVL, however, measuring CE of PVL is consider an alternative
solution to evaluate PVL severity due to difficulty to measure the regurgitation volume (Zoghbi et
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al., 2009). Nevertheless, the CE of PVL totally depends on capturing accurate images right at the
bottom level of TAV device. However, in case of multiple jets are presented, CE can be
misleading to estimate the severity of PVL. In the same manner, the CE has not been validated,
therefore, the PVL volume of a given CE is basically unknown. In this study, first we validated
the CE via CFD and in vitro investigation. Also, we introduce a new method based on fluid
dynamics to estimate PVL severity.
4.4.2 Validation of CE
In this chapter, an experimental setup was used to validate the most common
methodology that uses to estimate the severity of PVL post-TAVR procedure. To the reader
knowledge this is the first study that focused on validating CE with respect to different level of
severity experimentally. The CFD simulation was used to validate the CE guide, multiple PVL
severities were tested by increasing and decreasing the size of the gap as it shown in (Fig. 4.2).
The presented results of the CFD simulation indicates poor correlation between the calculated RV
and the estimated CE. The plot in Fig. 4.6 demonstrates that the CE overestimate the severity of
PVL. The result obtained from the CFD simulation support the clinical outcomes of several
studies (Pibarot et al., 2015, Hayek, 2014 #110 ). Additionally, an experimental setup was
developed to confirm the validity of the CFD simulation. Like the CFD, different level of PVL
severities were examined by increasing and decreasing the circumference of the introduced gaps
in (Fig. 4.3c). The in vitro result demonstrates a weak correlation between the measured RV and
the estimated CE. Also, the plot in (Fig. 4.9) illustrates that CE method overestimate the severity
of PVL. The boundary critical values for classification of PVL severity obtained from the in vitro
result match the CFD results, those values do not match the critical values presented in (Geleijnse
et al., 2015; Zamorano et al., 2011). Therefore, the in vitro results confirm the invalidity of the
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CE method. Therefore, developing a new approach based on fluid dynamic was highly
encouraged to develop an accurate way of estimating the severity of PVL post-TAVR.
In this study we proved that the CE method overestimate the severity of PVL, many
clinical data have suggested that totally depending on short axis images to estimate the severity of
PVL could be misleading. One of the most challenging associated with capturing images of PVL
is the moment to capture the location of leakage. In diastole, the base of the heart moves far away
from the heart apex (Zoghbi et al., 2009). Another issue is that in the present of multiple PVL
jets, different location might not be seen in one beat, but it can be seen in other phases of the beat
or in a different beat. This will lead to overestimate the real severity of PVL, even though in some
cases of a rocking TAVs PVL severity is most likely to be severe and not overestimated (van
Dalen et al., 2009).
4.4.3 Maximum Momentum Flux
In this chapter, we also introduced a new method based on estimating the maximum
momentum flux of the PVL leakage to evaluate the severity of PVL using parameters that are
currently being used to evaluate the severity of PVL. The maximum momentum flux is a
combination of the mass flow rate and the maximum velocity that driven the flow in the PVL
leakage. The new approach showed a significant correlation with respected to the measured RV
in CFD simulation and in vitro results with high value of R2. Both results demonstrate similar
boundary critical values between mild to moderate and moderate to severe as it shown in (Fig.
4.7) and (Fig. 4.11), which indicate the robust of the introduced approach. As we shown
previously that CE is not an accurate method to estimate the severity of PVL, and the obtained
critical values do not match those were introduced in the current guideline (Jilaihawi et al., 2012;
Zamorano et al., 2011). Moreover, the result obtained from the in vitro indicates no significant
variation between the estimated momentum flux and increasing of the mean aortic pressure as it
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shown in (Fig. 4.11). The plot in Fig. 4.11 shows that the momentum flux approach not only can
be used among patients with normal aortic pressure, even among patient with high blood
pressure. To the reader knowledge this is the first study that introduce and validate a new simple
approach based on fluid dynamics by using echocardiographic parameters.
Furthermore, the good agreements between CFD simulation and in vitro results in

term of calculating maximum momentum flux of the PVL jets, confirm the validity of our
assumption by neglecting the viscus forces of the flow in the duct. The in vitro result
indicates that the measured pressure in LVOT region increases with increasing RV,
however, the measured aortic pressure was not influenced with the severity of PVL.
Additionally, Table 4.3 demonstrate a significant increase of the LVOT pressure with
increasing the aortic pressure. High severity of PVL could lead to heart failure due to
expansion in the LV wall, especially when the LV exposes to high pressure. On the other
hand, the results obtained by echocardiography demonstrate that the captured area in
LVOT region changes significantly with respect to the applied pressure and the duct size
of the washer, however CE and PW velocities was remaining similar.
Currently several techniques can be used to estimate the severity of PVL post-TAVR
procedure, including magnetic respond imaging, cineangiography, aortic regurgitation index and
doppler echocardiography, however each of these techniques has its own limitation and technical
difficulties (Zoghbi et al., 2009). Classification of PVL based on hemodynamics measurements
can be challenging due to the natural of the PVL jet. Our experimental data shows the possibility
to estimate the severity of PVL without measuring RV of the leakage directly. Nevertheless, a
recent study addresses a way to estimate the severity of PVL by printing a 3D model of the
patient-specific geometry (Pibarot et al., 2015). However, the accuracy of the gap sizes might be
not accurate due to smoothing and removing difficult part to print, also the whole procedure is
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time consuming. Therefore, in this study we believe that the presented method provides well and
accurate way to generate multiple severity by controlling gap sizes as in (Fig. 4.3c). On the other
hand, a similar study suggested that increase mean aortic pressure lead increase in PVL RV
(Ripley et al., 2016). However, our experimental result shows no significant increase in RV with
respect to 100 and 120 mmHg.
4.5 Conclusion
In summary, TAVR has been introduced as an alternative procedure to surgical
replacement of aortic valve with less recovery time to SAVR. However, PVL is a frequent
clinical issue associated with TAV implantation procedure. Quantifying the severity of PVL
clinically is still challenging due to complexity of the PVL jets . CE is the most common
technique to estimate the severity of PVL. Nevertheless, in this chapter we demonstrated that CE
indicates to over-estimate the severity of PVL. Additionally, we introduced a new approach to
estimate the severity of PVL based on estimating maximum momentum flux of the PVL jets. The
new approached showed a good linear correlation with the measured RV. Therefore, the
maximum momentum flux approach is a more accurate method to evaluate the severity of PVL
post-TAVR procedure.
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Chapter 5: Quantification the severity of Paravalvular Leakage Based on Energy Loss
5.1 Introduction
Transcatheter aortic valve replacement (TAVR)is a less invasive procedure for aortic
valve replacement targeting selected patients whom considered risky for open-heart surgery,
recently the Food and Drug Administration (FDA) approved that younger patients can be
considered for TAVR (Tanaka et al., 2018). The transcatheter aortic valve (TAV) devices provide
similar benefits to surgical valve for patient who cannot undergo a surgical valve replacement
(Coylewright et al., 2020; Cribier et al., 2002; Grube et al., 2007) to receive treatment. Several
clinical studies have shown that TAVs provides superior systolic performance in term of mean
pressure gradient and effective orifice area (Clavel et al., 2009; Daubert et al., 2017; Webb et al.,
2007). However, paravalvular leakage (PVL) is a frequent clinical complication post-TAVR,
compared to surgical aortic valve replacement rarely (-6%) (Hahn et al., 2013; Ionescu, Fraser, &
Butchart, 2003). Mild to Moderate PVL might have little clinical impact among older patients
whom life expectancy is limited, however this degree of PVL severity will lead to more serious
clinical impact among TAVR younger patients. It has been illustrated that PVL is associated with
hemolysis and endocarditis even with mild PVL which result in ventricular dysfunction (Bhindi,
Bull, Schrale, Wilson, & Ormerod, 2008; Pibarot et al., 2015). Therefore, qualifying the severity
of PVL accurately is quite significant for clinical decisions.
Measuring hemodynamic performance of TAV such as blood velocity, pressure gradient
and effective orifice area could be used to evaluate the severity of PVL post-TAVR. However,
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none of these parameters take into consideration of measuring PVL volume. Based on these
parameters current TAV devices match and may even excessed the performance of surgical
valve(Azadani et al., 2009; Maraj, Jacobs, Ioli, & Kotler, 1998). Nevertheless, none of these
parameter take in consideration to evaluate the severity of PVL. Therefore, in this study we
develop a new methodology by using Doppler echocardiograph parameters that provides an
accurate estimation to quantify the severity of PVL based on the concept of energy loss.
Evaluating the performance of TAV devices depend on measuring hemodynamic parameters such
as pressure gradient, blood velocity and effective orifice area. Based on these parameters, TAV
devices match and may exceed the hemodynamic performance of surgical valves (Barakat et al.,
2018; Clavel et al., 2009). On the other hand, the circumferential extent and ½ pressure time of
PVL are the semi-quantitative parameters currently used to estimate the severity of PVL during
diastole (Walther & Falk, 2009). However, more recent data have demonstrated the accuracy of
energy loss in examine the performance of TAV devices (Akins, Travis, & Yoganathan, 2008;
Azadani et al., 2009; Pibarot et al., 2015).The energy loss concepts provide more accurate criteria
to evaluate and examine the total hemodynamic performance of TAV devices during the entire
cardiac cycle, and the effect of left ventricle workload during diastole (Garcia, Pibarot, Dumesnil,
Sakr, & Durand, 2000, Garcia, 2000 #12, Azadani, 2016 #122). In the cardiac cycle, the energy
exists in two forms: potential (in the form of pressure or height) and kinetic energy (in the form of
velocity). Color doppler imaging of PVL jets diameter and length illustrate in a semi-quantitate
way the kinetic energy across the TAV devices. Nevertheless, the summation of potential and
kinetic energy losses must be taken in consideration to evaluate the severity of PVL and to
determine the workload on the left ventricular. Additionally, substantial energy loss was
measured with TAV devices during diastole, even with mild PVL, TAVs implantation show
higher workload on the left ventricle than surgical implanted bioprosthesis (Akins et al., 2008).
Moreover, the energy loss has the potential to estimate the severity of aortic stenosis better than
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other semi-quantification parameters (Azadani et al., 2009). However, none of these studies have
considered measuring energy loss with respect to RV to address the appropriate classification of
PVL severity. In this study, we developed two methodologies to measured energy loss invasively
and non-invasively during the entire cardiac cycle and comparing invasive energy loss to noninvasive energy loss.
5.2 Material and Method
5.2.1 Energy loss Approach
In this study, we measured transvalvular energy loss in both invasive and non-invasive
for different degrees of severity of PVL during systole. The measured invasive energy loss is
based on the fundamental of conservation of energy. The invasive energy loss was measured by
measuring the instantaneous of flow (𝑄𝑣𝑎𝑙𝑣𝑒 ) and instantaneous of pressure gradient (∆P) using
the pulse duplicator based on the formula listed in Table 1 for both systole and diastole. The
pressure gradient measured using pressure transducer and the flow measured using flow
transducer as it shown in Fig 3. Where 𝑡𝑒𝑎𝑟𝑙𝑦−𝑠𝑦𝑠𝑡𝑜𝑙𝑒 the beginning of the forward flow through
the valve, 𝑡𝑒𝑛𝑑−𝑠𝑦𝑠𝑡𝑜𝑙𝑒 is the end of the forward flow through the valve, 𝑡𝑒𝑎𝑟𝑙𝑦−𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑒 is the time
of valve closure and 𝑡𝑒𝑛𝑑−𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑒 is the end of the cardiac cycle. The total invasive energy loss
was the sum of the energy loss in systole and diastole.
The non-invasive formal was driven from conservation of mass, energy and momentum.
The systolic non-invasive energy loss measurements were performed based on measuring the
maximum velocity of the SAPIEN 3 jet (𝑉𝑗𝑒𝑡 ) during systole using CW Doppler from long axis
view, the effective orifice area (EOA) was measured instantaneously using LABVIEW software
(BDC Labs, Wheat Ridge, CO, USA ) based on Gorlin equation, and 40 mm cross-section area of
the aorta (AA). On the other hand, the diastolic non-invasive energy loss measurements were
performed based on measuring 𝑉𝑣𝑐 using CW Doppler, ρ is the density of the running solution,
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RV was measured instantaneously using the flowmeter and K was calculated based on the
diastolic invasive energy loss measurements. The total non-invasive energy loss was the sum of
the energy loss in systole and diastole.
Table 5.1. Illustrates invasive and non-invasive energy loss formulas for the cardiac cycle.

5.2.2 Heart valves and PVL Model
To mimic the flow characterization in PVL, a 3D printed washer was used by introducing
anatomically realistic gaps was between the TAV geometry and the native TAV commissures
(Fig. 5.1a). A 26 mm SAPIEN 3 was implanted within the inner diameter of the 3D printed
washer (Fig. 5.1b) and placed in the aorta side. Also, a bileaflet mechanical heart valve was

placed at the mitral position. The 3D printed washer has an outer diameter of 40 mm, inner
diameter labeled as the SAPIEN 3 and height of 16 mm. chamber. The stages of PVL severity

was controlled by increasing and decreasing the circumference of the gaps, however, the
gap width was kept at 2 mm. The flow inside the gaps are govern by the pressure gradient
between aorta and left ventricle (Fig. 5.1c) chambers. The flow jet reaches its maximum velocity
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at the entrance of the duct . After that, the flow is confirmed by TAV’s geometry and the left
ventricle chamber, pressure and velocity based on the variation of the duct size.

Figure 5.1: (a) 3D-printed washer with 3 gaps. (b) A 26 mm Edwards SAPIEN 3 implemented
within the 3D-printed washer. (c) schematics show the flow through PVL channel.

5.2.3 In Vitro testing of TAVs
Multiple gaps size was tested in a custom-build pulse duplicator at room temperature developed
for heart valves testing (BDC Labs, Wheat Ridge, CO, USA) to obtain different PVL severity
stages. A Recirculating fluid of 36% by volume glycerin solution in phosphate buffered normal
saline solution which mimics blood viscosity and density at 37 °C was used as a blood analog
fluid. Flow circulation was simulated through silicon ventricular contraction, control of

82

compliance and peripheral resistance. Our pulse duplicator system was previously descripting in
more detail and validated (Garcia et al., 2000). The pulse duplicator input parameters matched the
international standard ISO 5840: 2015 recommendations for testing prosthetic heart valves; that
is, heart rate of 70 beats/min, mean aortic pressures of 100 mm Hg, and cardiac output of 5
L/min. these hemodynamics parameters were maintain constant through the experiment. Pressure
was measured in the aorta and left ventricle using strain gauge pressure transducers (Utah
Medical Products, Midvale, UT, USA). pressure measurements were taken at 105 mm
downstream and 35 upstream of the valves for aortic and left ventricle respectively. Additionally,
pressure transducers were calibrated prior to the tests using Delta-Cal Pressure transducer
simulator/tester (Utah Medical Products, Inc). In addition, an electromagnetic flowmeter (Model
501, Carolina Medical Electronics Inc, East Bend, NC, USA) was located on top of the aortic
valve and used to measure the regurgitation mass flow rate of the RV in the system. Additionally,
iE33 ultrasound system (Philips Medical Systems, Andover, Massachusetts) and a V-219 (2.5
MHz) was used to measure the velocity of PVL.

Figure 5.2: A custom-built pulse duplicator system (BDC Labs, Wheat Ridge, CO)
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5.3 Results
5.3.1 Invasive energy loss
The invasive energy loss was measured directly from the data obtained from the pulse
duplicator throughout the cardiac cycle. First, energy loss was measured at normal mean aortic
pressure of 100 mmHg, second, energy loss was measured at mean aortic pressure of 120 mmHg.
The pressure and flow curve in (Fig. 5.3) correspond to moderate case with RV of 48.51 ml/beat.
The blue sold line presents the instantaneous left vernacular pressure, while the dash red line
presents the instantaneous aortic pressure in (Fig. 5.3a). The green sold line corresponds to the
measured flow as it shown in( Fig. 5.3b). The pressure gradient was directly calculated by
subtracting left ventricular pressure from aortic pressure. The mean value of the pressure gradient
was used to measure the energy loss. Additionally, the volume of the leakage was considered as
the red area of the flow during diastole as it shown in (Fig. 5.3). The mean value of the flow was
used to measured energy loss. Moreover, the experimental data shows a significant increase in the
left ventricular pressure with increasing RV, which led to drop in the pressure gradient.
Fig. 5.4 demonstrates the variation in the measured energy loss invasively with the RV.
The plot shows a linear correlation between the measured RV and energy loss by using the
equation in Table 5.1, as it is evident from the value of R2. Note that both the presented data
corresponds to mean aortic pressure of 100 mmHg and 120 mmHg in Fig 5.4. The data in the
graph indicates that energy loss increases with increasing aortic pressure especially with moderate
and severe cases. However, according to the plot in Fig. 5.4, there is matching values of the
measured energy loss at 100 and 120 mmHg in the mild section especially. Additionally, two
critical values for quantifying the severity of PVL based on energy loss can be defined as, energy
loss between 318-635 mJ correspond to moderate, below 318 mJ and above 635 mJ correspond to
mild and severe, respectively. The linear correlation in Fig. 5.4 shows that there exists a one-one
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correspondence between RV of a PVL and its energy loss. Moreover, the bar charts in (Fig. 5.5)
demonstrate that the energy loss during diastole increases with increase PVL severity, however,
there is no direct correlation between systolic energy loss and PVL severity.

Figure 5.3: Pulse duplicator result with RV of 48.51 ml/beat. (a) pressure waveform of one cardia
cycle at mean aortic pressure of 100 mmHg, the blue sold line corresponds to aortic pressure, the
red dash line corresponds to left ventricular pressure. (b) the measured flow rate across the aortic
valve during the cardiac cycle, on the right, the red area in the right image shows the amount of
leakage during diastole.

85

Figure 5.4: Linear correlation between the measured regurgitation volume and the measured
energy loss invasively. Solid blue circle and empty diamond correspond to measured energy loss
at mean aortic pressure of 100 mmHg and 120 mmHg, respectively.

Figure 5.5: Chart bar shows the measured total energy loss invasively per cardiac cycle.
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5.3.2 Non-invasive energy loss
After measuring the energy loss invasively for multiple degree of PVL severity, the data
obtained from the echocardiography was used to measure energy loss non-invasively. The energy
loss was calculated at normal and high mean aortic pressure 100 mmHg and 120 mmHg,
respectively. The Echocardiography images in Fig. 5.6 demonstrate a moderate case with RV of
48.51 ml/beat. Long axis of the velocity jets is shown in Fig. 5.6a. The maximum velocity was
measured using CW Doppler along the velocity jet as it shown in Fig. 5.6b, the blue arrow
indicates diastolic velocity while red arrow indicates systolic velocity. The energy loss was
calculated based on the listed equation in Table. 1 non-invasive column throughout the cardiac
cycle. To calculate energy loss during diastole, Vvc was measured directly in the
echocardiography using velocity time integral function, while RV was directly measured in the
pulse duplicator. The regurgitation coefficient (K) value was calculated based on the measured
energy loss invasively. While the density was used as the running solution which is around 1.102
g/cm. On the other hand, the effective orifice area (EOA) was directly measured in the pulse
duplicator based on Gorline equation.
Fig. 5.7 demonstrates the variation in the calculated energy loss non-invasively with
respect to the measured RV. The plot shows a linear correlation between the calculated energy
loss based on the equation listed in Table 5.1 during diastole. An excellent correlation between
the measured RV and the calculated energy loss was observed, as its evident from the R2. The
plot shows values of energy loss correspond to mean aortic pressure of 100 and 120 mmHg solid
blue circle and empty diamond, respectively. Additionally, two critical values for quantifying the
severity of PVL based on energy loss can be defined as, energy loss between 255-510 mJ
correspond to modetrate, below 255 mJ and above 510 mJ correspond to mild and severe,
respectively. The linear correlation in Fig. 5.7 shows that there exists a one-one correspondence
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between RV of a PVL and its energy loss. Moreover, the bar charts in (Fig. 5.5) demonstrate that
the energy loss during diastole increases with increase PVL severity, however, there is no direct
correlation between systolic energy loss and PVL severity.

Figure 5.6: A sample of echocardiography parameters that were used to estimate the maximum
momentum flux. (a) Long axis view of the velocity jet, illustrating measurement locations. (b)
CW Doppler measurement of the maximum velocity of the jet at the vena contracta, red arrow
corresponds to systole and blue corresponds to diastole. (c) Short axis view of the area of the jets
in the LVOT region. (d) PW Doppler measurement of velocity magnitude at the location where
the area was estimated.
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Figure 5.7: Linear correlation between the measured regurgitation volume and the calculated
energy loss non-invasively. Solid blue circle and empty diamond correspond to measured energy
loss at mean aortic pressure of 100 mmHg and 120 mmHg, respectively.

Figure 5.8: Chart bar shows the calculated total energy loss non-invasively per cardiac cycle.
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5.4 Discussion
5.4.1 Summary
In the previous chapter we illustrated that the CE of PVL over-estimate the severity of
PVL, therefore we introduced a new methodology based on estimating the maximum momentum
flux of the PVL jet. In this chapter we introduce a new methodology based on the concept of
energy loss to quantify the severity of PVL. The concept of energy has been introduced before to
assess the severity of valvular stenosis (Barakat et al., 2018). In this study, energy loss was
measured invasively and non-invasively, the invasive energy loss measurement was performed
directly from the pulse duplicator using the instantaneous pressure and flow measurements. While
the non-invasive energy loss was measured directly from the data obtained from the
echocardiography. It was observed that energy loss has an excellent correlation with the measured
RV during diastole. The non-invasive energy loss estimation can be very helpful in determining
the severity of PVL accurately. Several studies indicate that measuring hemodynamic
performance of valvular leakage by measuring energy loss (Akins et al., 2008; Garcia et al.,
2000). However, to the reader knowledge, this is the first study that introduced and validated two
formula of energy loss invasively and non-invasively.
5.4.2 Energy loss Measurements
Energy loss is a well-founded engineering concept which allows assessment of
bioprosthetic heart valve performance during systole, and accounts for the impact of leakage
during diastole (Azadani et al., 2009). Evaluation of PVL severity based on energy loss provides
more detailed information than currently available semi-quantitative methods (Akins et al., 2008;
Zamorano et al., 2011). Totally depending on semi-quantitative parameters can be misleading,
especially under low cardiac output. This study demonstrates a one to one corresponding between
the measured energy loss invasively experimentally and the estimated energy loss non-invasively
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by echocardiography during diastole. Therefore, a good matching fitted line of R2 = 0.97 between
invasive and non-invasive energy loss with a slop of 0.9, which means the measured energy loss
in vitro and Doppler are almost identical as it shown in (Fig. 5.9). In this way, as the workload on
the left ventricle increases, the ventricle becomes the interest of evaluation. Additionally, In the
present of PVL, the ventricle must increase its systolic pressure and volume to compensate the
lost energy to maintain blood flow at a constant rate. PVL results in high stress applied into the
ventricle wall which could lead into a heart failure. Measuring energy loss is an excellent way to
estimate the severity of PVL and demonstrates the increase in workload on the ventricle.
Nevertheless, the concept of energy loss has not been mostly used clinically since its direct
estimation requires complex and invasive measurements of pressure and velocity (Zoghbi et al.,
2009).
In this study, the energy loss during systole was calculated as well, however there is no
direct correlation between systolic energy loss and RV. )Fig. 5.10( shows a one to one
corresponding between the total energy loss invasively and noninvasively R2 = 0.94 and a slop of
0.9. The linear correlation in )Fig. 5.10( indicates the possibility of using the totally energy loss to
evaluate the severity of PVL. Classifying the severity of PVL post TAVR based on energy loss
provides more detailed information than the currently semi-quantification methods by studying
the performance of the entire cardiac cycle. However, measuring energy loss clinically requires
complex and invasive measurement. Therefore, in this study we developed a non-invasive
approach by using echocardiography to measure energy. The in vitro energy loss measurements
show an excellent agreement with the measured energy loss using echocardiography. This is a
combination study to assess and quantify the severity of PVL by using maximum momentum flux
and energy loss concepts. Measuring RV is the most accurate way to determine the severity of

91

PVL, however, it’s an invasive and expensive procedure. Therefore, the maximum momentum
flux can be used to estimate RV, to measure energy non-intensively during diastole.

Figure 5.9: Linear correlation between the measured energy loss invasively and noninvasively
during diastole.

Figure 5.10: Linear correlation between the measured energy loss invasively and noninvasively
during the cardiac cycle.
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5.5 Conclusion
Measuring RV is the most accurate way of evaluating the severity of PVL, however there
is no clinical way to measure RV in patient via the current tools. On the other hand, energy loss is
a well-established engineering approach which provides evaluation of TAVs performance and
during systole and accounts for any regurgitation during diastole. TAV devices have emerged as
an alternative treatment for patients at high risk of open-heart surgery with severe aortic stenosis.
Nevertheless, PVL is still frequent clinical complication post TAV implementation. Estimating
the severity of PVL is still quite challenging, however, the good agreement between invasive and
non-invasive energy loss approves the ability of using energy loss to estimate RV non-invasively.
Additionally, we demonstrate the significant workload imposes in the left ventricle which could
lead to heart failure. Even with the last generation of TAVs, PVL is expected to remain one of
the major clinical issue post TAV implementation.
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Chapter 6: Conclusion and Future work
TAVR is a minimally invasive treatment to replace a calcified aortic valve or a
degenerated surgical bioprosthetic valve. Unlike surgical valve, TAVR is delivered through a
catheter to the affected valve. Previously, the FDA approved TAVR only in patients at high risk
of open-heart surgery with limited life expectancy. Recently, the FDA approved TAVR in young
patients at low risk of open-heart surgery. In contract to SAV, there are no enough clinical data in
term of the fluid dynamics performance of TAV devices. Another clinical challenging is
associated with evaluating the performance of TAV post the operation non-invasively and
evaluate the overall performance of the valve. Therefore, experimental testing and computational
modeling become an important part to evaluate the performance of TAV devices. Consequently,
the objectives of this dissertation were to employ experimental testing to investigate the source of
clinical issues that are associated with TAV devices, and to validate computational modeling
which were developed to obtain close visualization of areas where it’s impossible to visual
experimentally.
It’s been demonstrated that the velocity profile generated by TAVs has been known to
play a critical role in thrombotic and hemolytic complications associated with prosthetic heart
valves. Therefore, the main goal of this dissertation was to investigate weather stroke happened
due to shear induced in TAVs, also to explain the reason behind valvular thrombosis among
TAVR patients. Additionally, there is a lack of validated method to estimate the severity of PVL.
Thus, I validated semi-quantitative methods that are commonly used to assess the severity of
PVL post-TAVR. In the same manner, I introduced a new methodology to classify the severity of
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PVL based on fluid dynamics using parameters that can be measured using echocardiography.
Moreover, Energy loss is an excellent parameter to evaluate the performance of TAVs, not only
allows evaluation of TAV performance during systole, but also allows quantification of
PVL during diastole. Therefore, developing and validating non-invasive procedure to estimate
energy loss post-TAVR during the cardiac cycle were performed and the workload imposes on
the left ventricle was measured.
6.1 Conclusion
Several clinical data have revealed high rate of cerebral emboli among TAVR patients,
even in a short time after the procedure. On the other side, it’s been known that fluid dynamics
play an important role in understanding progression of diseases that are associated with TAVs
such as stroke. In this study, the velocity and shear stress magnitude downstream of two
commercially available TAV devices were measured throughout a cardiac cycle. Additionally,
the hemodynamic performance of TAV devices was compared to a surgical valve in term of
mean pressure gradient and orifice effective area. The result of this study revealed that shear
stress magnitude of TAV devices was only detected at the peak of flow with low magnitude. The
hemodynamic performance of TAVs were comparable and even exceed the performance of the
surgical valve. The detected shear stress was below the known threshold for red blood damage
and platelet activation. Therefore, it’s unlikely that stroke accrue due to high shear induced in
TAVs.
Reduced leaflet motion due to valvular thrombosis has been observed among TAVR
patients even in a few days after the procedure. Valvular thrombosis was predominantly found on
the aortic surface of the valve leaflets. To address the cause of thrombosis formation on TAV
leaflets, experimental testing and computational modeling were developed. The hypothesis of this
study was based on investigating blood stasis in geometric confinement of TAV device. The
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experimental flow field was obtained to validate the flow field that was obtained from the
computational simulation. In this study two geometrical models were developed; one represents
surgical valve and the other represents the geometric confinement of TAV. After validating the
flow field of the simulation, a randomly distributed massless particles were generated in the flow
field in both models. The result of this study illustrated longer particles stasis in TAV model in
compare to the surgical valve model where the particles washed away especially during diastole.
Therefore, we could conclude that the geometric confinement of TAV increase blood stasis
between the outer surface of TAV leaflet and the inner surface of the calcified valve, which
increase the likelihood of thrombosis formation on TAV leaflet.
PVL is a frequent clinical complication post-TAVR procedure due to the natural of TAV
implementation. Unlike surgical valve where the calcified valve is removed and replace it with a
bioprosthetic valve, TAV is implanted over the calcified valve or a degenerated bioprosthetic
valve (ViV). The only accurate way to estimate the severity of PVL is by measuring leakage
volume directly, however, measuring PVL volume is significant challenging and pricy.
Nevertheless, there is a lack of validated protocol to evaluate PVL post TAVR and ensure
appropriate classification of its severity. On the other hand, the CE of PVL was introduced by to
estimate the severity of PVL non-invasively. The goal of this study was to validate CE of PVL
experimentally, and to introduce a new methodology base on fluid dynamics to estimate the
severity of PVL. The result of this chapter illustrated that CE over-predicate the severity of PVL,
and its shown poor correlation with the measured RV. However, the maximum momentum flux
of PVL shows an excellent correlation with the measured RV, which could be used as a new tool
to assess the severity of PVL post TAVR.
Energy loss is a well-established engineering approach that use to evaluate the
performance of bioprosthetic heart valves post procedure. Substantial energy loss during diastole
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occurs due to PVL, even in the presence of mild PVL. The concept of energy loss has not been
widely used in clinics, because the measurement of energy loss in patients require invasive
measurements of instantaneous temporal of pressures and velocities directly from the heart.
However, in this study we developed a method to estimate energy loss non-invasively using
doppler echocardiography. In this work the invasive energy loss was measured directly from the
pulse duplicator, while the non-invasive energy loss was calculated using parameters obtained
from the echocardiography. The result of this study demonstrated a significant correlation
between the measured RV and energy loss invasively. The energy loss obtained from noninvasive measurements match well with invasive measurement. Therefore, energy loss could be
used to estimate the severity of PVL accurately. Also, the experimental results showed significant
workload on the left ventricle due the present of PVL jets. Energy loss could be used as a
quantitative parameter to quantify the severity of PVL precisely.
6.2 Future Works
A few limitations are associated with the study in chapter 2 that should have been
addressed as future work. In this chapter, we only used two commercially available of TAV
devices which were SAPIEN 3 and CoreValve because they are widely used in clinical trial and
practice. However, each year the heart valve industries release different designs and
configurations of TAVs, therefore, studying the flow field of the most recent generation of TAVs,
will benefit in validating computational modeling. To understanding the structure of flow field
during diastole, a 3D-PIV system should be used to obtain flow field of TAVs. In addition,
multiple parameters such as Reynold shear stress (RSS) and vorticity should be measured.
Furthermore, Echo-PIV can be performed in the future simultaneously to assess the overall
performance of TAVs in term of hemodynamics measurements.
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In this dissertation, we developed a hypothesis to address the issue behind reduced leaflet
motion among TAVR patients. Due to the complexity of the TAVR setting, we used a validated
computational modeling to visualize the blood motion between the calcified valve and TAV using
BRT approach. Applying the BRT approach to address the likelihood of thrombosis formation in
patients post transcatheter mitral valve replacement (TMVR). In addition, testing multiple
devices of TAV could be more valuable since super-annular valve such as CoreValve might not
show large BRT in compare to annular valves such as SAPIEN 3. Also including valves types,
size and positioning of TAV device, as well as considering anatomic structure such as coronary
and non-coronary leaflets in the CFD-model.
In this dissertation we illustrated that the CE of PVL over-estimate the severity of PVL
post-TAVR procedure. The introduced non-invasive energy loss formula cannot be accomplished
without estimating RV of the PVL. Therefore, the maximum momentum flux method can be used
to estimate RV first in the future, then the obtained RV can be used to calculated energy loss noninvasively. Additionally, we would like to see the energy loss method being applied to large
population of TAVR patients non-invasively.
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